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Cytotoxic Lymphocyte destroying a Tumor 
Cell. 
The outer membrane of the tumor cell (right) 
has been shot full of holes by perforin, 
secreted from the cytotoxic T lymphocyte 
(left).  
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1 Summary 
Lung cancer is the leading cause of cancer-related mortality in the world, whereby 
Non Small Cell Lung Carcinomas (NSCLC) constitute 80% of all lung tumors. 
Whereas in Stage I and II NSCLC surgical resection with or without adjuvant 
chemotherapy currently represents the most frequently applied treatment, in late 
stage NSCLC, representing 70% of all cases, chemotherapy or radiotherapy are 
mainly palliative. Thus, the poor prognosis and the limited therapeutic options 
available urge the development of new approaches. Among these, active specific 
immunotherapy targeting Cancer/Testis Antigens (CTA) might represent a valuable 
additional treatment in NSCLC. 
CTA have been shown to represent promising targets in different types of cancer as 
they are silent in healthy adult tissues except in testis and placenta. These tissues do 
not present antigenic epitopes as they are deficient in MHC expression. Moreover, 
CTA are expressed by various tumors of different histology, stage and grade, and in 
some tumors, expression has been found to be correlated with poor disease specific 
survival. 
In this study first the prevalence and expression patterns of several CTA (MAGE-A1, 
-A2, -A3, -A4, -A10, -A12 and NY-ESO-1) in freshly excised NSCLC were 
investigated at gene and protein level. Tumor specimens (12 adeno-, 17 squamous 
cell and 4 large cell carcinomas) were obtained from HLA-A*0101 and/or             
HLA-A*0201 positive patients. CTA expression was detected in five adeno-, eight 
squamous cell and in two large cell carcinoma samples (45.5%). MAGE-A10 and       
-A12 were the most frequently (10/15 and 12/15 specimens, respectively) and 
MAGE-A1, -A4 and NY-ESO-1 the least frequently expressed genes (6/15, 6/15 and 
4/15 specimens, respectively). In 10/15 positive cases at least four CTA genes were 
concomitantly expressed. These results at gene level were widely confirmed by 
protein detection, the few discrepancies being explained by focal CTA expression 
limited to defined tumor areas.  
Immune responsiveness towards MAGE-A1 and -A3 (HLA-A*0101 restricted), 
MAGE-A4, -A10, multi-MAGE-A (an epitope shared by several MAGE-A antigens) 
and NY-ESO-1 (HLA-A*0201 restricted) epitopes was evaluated in cancer patients to 
assess whether a specific cellular response could be detected or generated upon ex 
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vivo stimulation. Induction of CTL was performed on expanded CD8+ T lymphocytes 
infiltrating the tumors (TIL), possibly enriched in activated specific T cells, eventually 
due to the presence of antigen. After successful expansion, CD8+ cells were 
repeatedly stimulated with autologous mature IL-4-DC pulsed with CTA peptides 
and/or infected with a recombinant vaccinia virus (rVV) encoding the corresponding 
epitopes together with the gene encoding human CD80. These vectors were 
constructed during the present study to provide highly effective immunogenic 
reagents with the perspective of possible clinical application.  
CTA specific CTL response could be observed in 7/26 populations. In six cultures, 
cytotoxic activity was low and did not correlate with expression of specific CTA in the 
original tumor specimens. These CTL responses could possibly be attributed to a 
primary in vitro sensitization. However, in one case stimulation of TIL with rVV 
infected APC revealed a high level of MAGE-A10 specific CTL response detectable 
by cytotoxicity assays and multimer staining. The corresponding gene, encoding the 
target epitope, was highly expressed in the original tumor.  
In NSCLC, CTA specific CTL sensitization in TIL, as detectable upon repeated 
stimulation with a panel of well defined peptides and highly effective APC, is rare. On 
the other hand, strong CTA specific CTL responses could frequently be generated 
from peripheral blood lymphocyes of healthy donors, upon stimulation of large 
numbers of effector cells with antigen pulsed DC obtained by GM-CSF/IFNα 
induction. 
The concomitant expression of multiple CTA in NSCLC and the possibility of natural 
CTL responses in these cancers may support the development of specific 
vaccination protocols using multi antigen vaccine preparations of CTA. 
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2 Introduction 
2.1 Immune system 
The cellular immune system consists of two parts cooperating in the maintenance of 
healthy state. While the innate immune system, consisting of macrophages and 
natural killer cells, is the first alerted by potentially harmful stimuli, the adaptive, 
specific immune system (B and T cells) amplifies the protective mechanisms of non-
specific immunity by focusing on specific antigens.  
The specificity of lymphocyte responses resides in their surface receptors (B or T cell 
receptors, BCR and TCR) recognizing oligoaminoacidic structures whose triggering 
results in the production of antibodies (humoral immunity), or in the generation of 
cell-mediated immunity, respectively. Every BCR or TCR on an individual B or T cell 
has a unique specificity, resulting from somatic gene recombination, leading to an 
enormous diversity of B and T cells.  
T cell selection processes take place in the thymus. As soon as the cell surface 
receptor is somatically rearranged, T cells pass positive selection by specific        
self-recognition of major histocompatibility complexes (MHC) and negative selection 
by demonstrating lack of specificity towards self-antigens. Mature T cells leave the 
thymus, enter the blood stream and migrate to the peripheral lymphatic organs. 
These selection processes are of particular importance for T cells, which cannot only 
directly kill virus infected cells or tumor cells, but also control the activation of other 
immune effector cells like, for instance, B cells. 
For specific activation of each T cell subpopulation, potential target proteins must be 
fragmented and recognized in association with MHC products expressed on the 
surface of nucleated cells.  
MHC class I molecules are expressed on the surface of all nucleated cell types. 
Cytotoxic T cells (CD8+ T cells), capable of causing target cell lysis once activated, 
recognize antigenic peptides only in association with MHC class I molecules. In 
contrast, helper T cells (CD4+ T cells) need to recognize peptides associated with 
class II MHC to secrete lymphokines, attract neutrophils, and enhance the ability of 
macrophages to engulf and destroy microbes. MHC class II molecules are 
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prevailingly expressed on the surface of antigen presenting cells (APC), the most 
important ones being macrophages, B cells, or dendritic cells (DC). 
2.1.1 Antigen presenting cells 
Main properties of APC are the ability to process endocytosed antigens and the 
expression of MHC molecules on their surfaces together with co-stimulatory 
receptors such as CD80 and CD86. The latter are among the molecules which 
distinguish professional antigen presenting cells such as DC from other MHC class II 
positive cells. 
Upon stimulation by inflammatory challenges, APC mature and migrate to the spleen 
and lymph nodes to induce specific immune responses. 
Triggering of CD40 receptor on APC by CD40 ligand (CD154), expressed on helper 
T cells, next to pathogenic stimuli may enhance the maturation process, as shown by 
increased expression of MHC, costimulatory factors, adhesion molecules, specific 
cytokines (IL-12, IL-15, TNF) and chemokines.  
2.1.1.1 Antigen processing and presentation  
The path leading to the association of protein fragments with MHC molecules differs 
for class I and class II restricted antigens. While MHC class II molecules present 
fragments derived from extracellular (exogenous) proteins, MHC class I molecules 
present peptides derived from cytosolic degradation of endogenously produced 
proteins.  
Proteins are fragmented in the cytosol in proteasomes. Fragments are then 
transported across the membrane of the endoplasmic reticulum by transporter 
proteins (TAP). Synthesis and assembly of class I heavy chain, beta2 microglobulin 
and peptides occur in the endoplasmic reticulum. Stable complexes are then 
transported to the cell surface. 
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2.1.2 Cytotoxic T cell activation 
T cells reside in secondary lymphoid organs waiting for presentation of foreign 
antigens by APC migrating from periphery. Additional to the engagement of the TCR 
with MHC/Ag, co-stimulatory signals from the antigen-presenting cell are required, 
providing additional control mechanisms that prevent inappropriate and hazardous T 
cell activation. The signals may be provided by cytokines secreted by helper T cells 
or by costimulatory receptors expressed on professional APCs. 
The CD28/CD80 or CD86 receptor/ligand system is one of the dominant                 
co-stimulatory pathways. Interruption of this signaling pathway with CD28 
antagonists not only results in the suppression of the immune response, but, in some 
cases, may induce antigen-specific tolerance.  
 
 
          
 
Figure 2.1: Stimulation of cytotoxic T cell for potent cytolytic immune response. 
Additional to TCR/MHC-Antigen binding, receptor/ligand formation of co-stimulatory 
factors are required for specific T cell activation. Upon stimulation, cytokines are released 
for further activation of the effector cells.   
 
 
Upon activation, cytotoxic T cells migrate to sites of infection or, eventually, 
neoplastic growth, to kill target cells by a combination of apoptosis and osmotic lysis. 
Release of secretory granules, containing perforin and granzymes, induces 
membrane pore formation triggering osmotic swelling and lysis. In addition, 
interaction of T cell Fas ligand with the Fas receptor of target cell activates the 
caspase proteolytic cascade and other pathways involved in apoptosis.  
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2.2 Cancer 
Despite a decrease in overall incidence, cancer remains a major public health 
problem. Each year 10.9 million people worldwide and 2 million in the European 
Union (EU) are diagnosed with cancer. There are 6.7 million (over 1 million in the 
EU) deaths from the disease, rates varying by gender and ethnicity [Jemal et al., 
2005].  
In the EU, cancer is a major cause of morbidity. 59% of people diagnosed with 
cancer are aged over 65 and around one out of three people will be diagnosed with 
cancer during their lifetime [Becker, 1998].  
After heart diseases, cancer is the second leading cause of death in Switzerland 
(Figure 2.2). 28% of death in men and 21% in women were caused by cancer in the 
year 2002. 
 
 
           
 
Figure 2.2: Death causes in Switzerland, 2002.  
Source: ‘Statistik der Schweiz’, Bundesamt für Statistik (BFS), Neuchâtel 2005  
 
 
The list of potentially causal and risk factors associated with cancer in 
general includes genetics (family history), behaviour (tobacco use, etc) and 
environment (radiation, etc). They all ultimately lead to dynamic changes in the 
genome driving the progressive transformation of normal human cells into malignant 
derivatives. 
Tumorigenesis in humans is a multistep process. A multiplicity of changes, such as 
self-sufficiency in growth signals, limitless replicative potential, sustained 
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angiogenesis, capacity of tissue invasion and metastasis, insensitivity to               
anti-proliferative signals and evasion from apoptosis, collectively dictate malignant 
growth by breaching anti-cancer defence mechanisms [Hanahan and Weinberg, 
2000].  
These acquired capabilities are due to alterations in regulatory circuits that govern 
normal cell proliferation and homeostasis: mutations of the receptors or transcellular 
signal transducers or of the end target gene of the pathway itself. Common 
manifestations are overexpression of specific oncogenes (ras, c-myc, etc) and 
downregulation of tumor suppressor genes such as p53, [Robles et al., 2002]. 
Furthermore, beside autonomous mechanisms, mutant cancer cells can achieve 
heterotypic signaling between diverse cell types within a tumor by conscription and 
subversion of normal cells serving then as active collaborators in tumor cell 
deregulated proliferation.  
These capabilities are probably shared by most types of human tumors. The paths, 
however, which cells take on their way to becoming malignant, are highly variable. 
Mutations in certain oncogenes and tumor suppressor genes can occur early in some 
tumor progression pathways and late in others. As a consequence, the acquisition of 
specific biological capabilities may appear at different times during progression. 
Finally, while in certain tumors a specific genetic event may per se contribute only 
partially to the acquisition of a single feature, in others, this event may aid in the 
simultaneous acquisition of several distinct characteristics.  
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2.3 Lung cancer  
2.3.1 Epidemiology 
Worldwide, lung cancer is the most common cause of cancer-related death. Since 
1930, frequency of lung cancer as death cause increased constantly in men until it 
became, in the early 50ies, the leading cancer-related cause of death. Until the 90ies 
the rate of lung cancer death continued to increase dramatically. In comparison, 
prostate cancer became more important in the 80ies but the death rate remained still 
much lower (Figure 2.3A). In women, lung cancer death rate started to increase in 
the 60ies until it became a leading death cause before breast cancer in the 80ies 
(Figure 2.3B).  
In the European Union lung cancer is the third most commonly diagnosed cancer 
(243 600 estimated cases in 2000). It affects men more than women, with the male: 
female ratio around 4:1.  
  
A      B  
 
Figure 2.3: Cancer related death rates in the United States, from 1930 until 2000.   
A: Death rates among males; B: Death rates among females;  
Source: Cancer Statistics, 2005, CA A Cancer Journal for Clinicians 2005 
 
 
Lung cancer is usually caused by a chronic exposure of the bronchial epithelium to 
multiple carcinogenic agents. The number of cases attributable to tobacco smoking 
varies between countries and regions depending on the historical levels of smoking 
for those regions. A recent estimate for Europe suggested that 90% of male and 60% 
of female lung cancers were caused by exposure to cigarette smoke. Besides 
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smoking, a small number of genetic polymorphisms have been associated with 
modest increases in lung cancer risk, thus excluding existence of highly-penetrant, 
strongly-predisposing genetic variants [Kiyohara et al., 2002]. 
In early stages of disease, lung cancers tend to be asymptomatic. As a 
consequence, most tumours are metastatic at the time of diagnosis (stages IIIB - IV, 
see below). Localised cancers (stages I - IIIA), resectable with available curative 
treatments, are only identified in approximately 20% of patients. Generally advanced 
stage at diagnosis implicates mostly non curative, palliative treatments and the 
relative resistance of the disease to currently available anti-cancer drugs leads to a 
high mortality rate, with 5-year survival typically between 10 and 15%. 
2.3.2 Lung cancer forms 
Lung cancers are generally heterogeneous, consisting frequently of cells of different 
histological subtypes. Still, pathological classifications emphasise the major cell type 
present in the tissue. Two broad categories of small cell lung cancers (SCLC), 
representing 20-25% of all bronchial carcinomas and non small cell lung cancers 
(NSCLC), representing 75-80% of cases, account for a large majority of lung 
cancers. Rarer tumor types such as carcinoids, carcinosarcomas, pulmonary 
blastomas and giant and spindle cell carcinomas are infrequently detected.  
SCLC mostly arise centrally in a large bronchus. They grow extremely fast, are highly 
invasive and highly metastatic. Therefore, these types of tumors have a severe 
prognosis with a 3-year survival of less then 10%.  
NSCLC are subdivided into three main histological subtypes, squamous cell lung 
carcinoma (35-40%), adenocarcinoma (25-30%) and large cell carcinoma (10%). 
Squamous cell lung carcinomas generally arise centrally within the lungs inside a 
large bronchus although they may sometimes be peripheral. Adenocarcinomas tend 
to occur in more peripheral locations arising from smaller airways but they can be 
found centrally in a main bronchus.  
Large cell carcinomas are undifferentiated tumours which lack the diagnostic features 
of the other subtypes.  
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2.3.3 Staging 
Lung cancers are classified according to UICC (International union against cancer) 
criteria. NSCLC patients are divided into different groups based on the standard TNM 
classification system, incorporating tumor size and location (T), lymph node 
involvement (N) and presence of distant metastases (M). 
Tumors of stage I have a maximum primary tumor size of 5cm with the exclusion of 
local or distant metastasis (T1-2 / N0 / M0). For Stage II cases, the primary tumor has 
a minimum dimension of 5cm or extends to the breast wall or skin (T3-4 / N0 / M0). 
Stage III includes primary tumors of any size with local metastases affecting lymph 
nodes (T1-4 / N1-2/ M0). The highest stage tumors (Stage IV) present distant 
metastases in liver, skeleton, brain or adrenal glands (T1-4 / N0-3 / M1). The size of 
the primary tumor represents no crucial prognostic factor. 
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2.4 Cancer therapy 
The primary objectives of cancer treatment are cure, prolongation of life, and 
improvement of the quality of life. Treatments usually include surgery, radiation 
therapy, chemotherapy, hormonal therapy, or combinations of them. The most 
advanced forms of treatment may produce 5-year survival rates of 75% or more for 
certain types of cancer e.g. cancer of the uterine corpus, breast, testis and 
melanoma. By contrast, 5-year survival rates in cancers of the pancreas, liver, 
stomach and lung are generally less than 15%. 
2.4.1 Immunotherapy 
Immunotherapy has matured as an additional treatment modality in the management 
of cancer. Two major approaches can be distinguished, passive immunotherapy, 
providing directly specific effector cells or antibodies, and active immunotherapy, 
requiring the participation of patients’ own cells to elicit anti-cancer effects. The latter 
can be further divided in non-specific and specific active immunotherapy. 
In active, non antigen specific immunotherapy multiple clinical trials have evaluated 
immunomodulators such as IFN-a (Phase I/II), BCG (Phase I/II) and Mycobacterium 
vaccae (Phase II) for the treatment of lung cancer [Agarwala et al., 2000; Millar et al., 
1982; O'Brien et al., 2000]. These agents are thought to induce both cellular and 
humoral anti-tumor immunity by inducing strong inflammatory responses. However, 
the success of these immunomodulators in cancer immunotherapy has been very 
limited (no significant clinical responses by systemic application). Still, there has 
been a resurgence in these approaches by targeting co-stimulatory molecules such 
as B7 family members, CD40L and others [Raez et al., 2003]. 
In contrast, specific cellular immunotherapy focuses on therapeutic vaccination using 
autologous or allogeneic tumor cells, tumor cell lysates or defined antigens. Cancer 
vaccines induce anti-tumor immune responses mediated by effector cells including 
CD8+ and CD4+ T lymphocytes. This type of therapy is tumor specific and has a 
relatively low systemic impact.  
Immune responses induced by vaccines that use whole tumor cells or tumor cell 
lysates instead of defined antigens are sometimes difficult to evaluate, as          
target-specific read-outs are not available.  
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On the other hand, a major limitation of peptide-based vaccination strategies is 
usually represented by the selective induction of CD8+ T cells against individual 
antigens. Antigen-specific CD4+ T cell responses and antigen-specific antibodies are 
less frequently involved. Using different immunostimulators such as cytokines (IL-2, 
IL-12, GM-CSF) or others adjuvants (CpG, incomplete Freund adjuvant) [Wilson et 
al., 2006] immune responses may be enhanced. 
Tumor antigen-specific strategies imply the use of immunodominant peptides alone, 
protein- or peptide-pulsed dendritic cells, or antigens and co-stimulatory proteins 
simultaneously expressed by viral vectors. Preclinical and clinical studies are 
addressing immune responses, clinical outcome, feasibility and safety of different 
treatment approaches. Although the induction of antigen specific responses is 
frequently reported, clinical effectiveness is mostly limited. 
2.4.2 Therapy for NSCLC 
The prognosis of NSCLC patients is mainly dependant on the stage of the tumor, 
with 5-year survival ranging from 60-70% for early disease (stage I) to <1% for stage 
IV disease. 
Treatment modalities currently employed are limited. Next to surgery, chemotherapy 
and/or radiotherapy may be used in patients who are not eligible for surgery. In 
metastatic NSCLC, primary chemotherapy is usually given with palliative intention. 
For radiotherapy, a radiation dose of 40 Gy or more in many fractions is commonly 
used.  
There is an urgent need for new adjuvant therapies possibly effective in lung cancer 
with lower associated toxicity than chemotherapy.  
2.4.3 Immunotherapy in NSCLC 
In NSCLC immunotherapy could be considered as an additional treatment or even as 
a replacement of current therapeutic approaches. Clinical studies are evaluating a 
variety of antigen formulations, such as autologous or allogenic tumor cell vaccines, 
modified virus, pulsed autologous DC, or dexosomes, DC released vesicles, for their 
capacity to induce cancer-specific anti-tumor immunity.  
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A number of authors have attempt the generation of cellular immune responses by 
targeting Her-2/neu, MUC1 or CEA652 by peptide-based vaccination [Disis et al., 
2002; Itoh et al., 2002; Kontani et al., 2003]. On the other hand, different studies aim 
at generating humoral responses targeting, for example, epidermal growth factor 
receptor bearing cells (EGF vaccine therapy; [Gonzalez et al., 2003]).  
To increase the efficacy of vaccines, immunomodulators or adjuvants are frequently 
used to enhance specific immune responses. Vaccines including irradiated viable 
autologous tumor cells admixed with non-specific immunostimulant bacillus 
Calmette-Guerin (BCG modified tumor cell vaccine) showed no clear benefit [Schulof 
et al., 1988]. In contrast, allogeneic vaccination with CD80 and HLA gene-modified 
adenocarcinoma cell lines (phase I) [Raez et al., 2004] or autologous tumor cell 
vaccines expressing granulocyte macrophage colony-stimulating factor (GM-CSF) 
(phase I/II, [Nemunaitis et al., 2004]) have shown more promising results.  
However, although a number of different immunotherapeutical procedures 
demonstrated some ability to induce anti-tumor immune responses in NSCLC, as 
illustrated sometimes by metastases shrinkage, responses were usually short-lived.  
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2.5 Tumor associated antigens 
In the past 20 years, there has been a continuing search for tumor associated 
antigens (TAA), which could be used to direct the cytolytic potential of the human 
immune system against cancer. Human TAA can be classified, based on their 
expression pattern, into four major groups: while unique antigens can be 
distinguished from shared antigens, the latter group can be further divided into  
tumor-specific antigens, differentiation antigens and overexpressed antigens. 
Unique antigens result from point mutations in defined genes potentially implicated in 
tumoral transformation. As these mutations are usually not shared by tumors from 
different patients, such tumor-specific antigens may only play an important role in the 
natural anti-tumor immune response of individual patients.  
On the other hand, shared antigens are present on tumors from different patients and 
histologies. While cancer/testis antigens (CTA) are silent in healthy adult tissues 
except testis and placenta, and can therefore be considered as operationally    
tumor-specific, differentiation antigens are also expressed in the normal cells of the 
same tissue from which a tumor developed. Antigens of this last group represent 
specific markers for a cell lineage (tyrosinase, carcinoembryonic antigen (CEA), 
prostate specific antigen (PSA), etc) and are not tumor-specific. Their use as targets 
for cancer immunotherapy may result in auto-immunity towards the corresponding 
normal tissue (e.g. vitiligo in the case of melanocytes). The third group of shared 
antigens, such as MUC1 and Her-2/neu, comprise antigens expressed in a wide 
variety of normal tissues and overexpressed in tumors. The low level of expression in 
normal tissues should not implicate autoimmune damage, although a threshold is 
frequently difficult to define.   
2.5.1 Cancer/testis antigens 
2.5.1.1 Classification 
About 90 cancer/testis antigens (CTA) grouped in over 40 families have been 
identified so far (see appendix I). The first CTA, the melanoma-associated antigen 
(MAGE) gene MAGE-A1, was characterized in 1991 through a newly developed 
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methodology for identifying tumor antigens based on tumor-specific CTL recognition 
[van der Bruggen et al., 1991].  
Further analysis of the MAGE-A family revealed twelve closely related genes 
clustered at Xp28 [Chomez et al., 2001]. Other clusters of MAGE genes were rapidly 
identified, such as MAGE-B and MAGE-C, as well as B antigen (BAGE) and             
G antigen I (GAGE1). Tumor-antigen genes structurally different from MAGE were 
also discovered using similar techniques.  
A new methodology, based on the screening of cDNA expression libraries with 
antibodies from patients’ sera (SEREX), led to the identification of several categories 
of CTA such as SSX [Sahin et al., 1995], synaptonemal complex protein 1 (SCP1) 
[Tureci et al., 1998] and the highly immunogenic cancer antigen New York 
oesophageal squamous cell carcinoma 1 (NY-ESO-1) [Chen et al., 1997].  
22 CTA families are encoded on the X chromosome (CT-X antigens). Many of them 
encode proteins with very high sequence similarities.  
2.5.1.2 Expression 
Proteins of the CTA families are expressed in a variety of malignant neoplasms, but 
silent in normal tissues except testis and placenta. Within the testis, CTA expression 
is restricted to germ cells [Jungbluth et al., 2000], while within the placenta they are 
expressed in the trophoblasts [Rimoldi et al., 1999; Simpson et al., 2005]         
(Figure 2.4). As these cells do not express MHC class I molecules, specific gene 
expression will not result in the presentation of antigenic peptides. 
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Figure 2.4: Cancer/testis antigen expression in normal tissues. 
Immunohistochemical staining of MAGE-A. left: staining of spermatogonia (testicular 
germ cells). right: staining of trophoblastic epithelia of placental villi. 
Source: Cancer/testis antigens, gametogenesis and cancer. Nature Reviews, Cancer 
2005  
 
 
The expression of CT antigens varies between tumor types. While bladder cancer, 
lung cancer, ovarian cancer, hepatocellular carcinoma and melanoma frequently 
express CTA, these antigens were rarely observed in renal cancer, colon cancer, 
gastric cancer and leukaemia. Different studies demonstrate that CTA can highly be 
expressed within tumor tissues [Sugita et al., 2002] but, interestingly, rarely in 
homogeneous form by all tumor cells [Jungbluth et al., 2000].  
The induction of CTA expression appears to be related to promoter demethylation 
[De Smet et al., 1996; Weber et al., 1994]. All CTA genes studied have methylated 
CpG islands within their promoters in normal somatic tissues, which may be 
responsible for the gene silencing [De Smet et al., 1999]. In contrast, in embryonic 
cells, CTA gene promoters have much less CpG methylation [Reik et al., 2001].  
During tumorigenesis, global DNA hypomethylation and gene-specific 
hypomethylation is a known occurrence. A recent study indicated that 
hypomethylation in tumors is frequently associated with hypermethylation of      
tumor-suppressor genes [Kaneda et al., 2004]. However, hypomethylation alone is 
not sufficient for the induction of CTA expression, as DNA in colon cancer cells, for 
example, is frequently hypomethylated [Goelz et al., 1985], even though CTA gene 
expression is rare in this tumor type. 
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2.5.1.3 MAGE family 
Based on sequence homologies many MAGE genes have been identified and 
classified into two subgroups: I, including MAGE-A, -B and -C, and II, including 
MAGE-D, -E, -F, -G and -H. In contrast to the genes of subgroup I, belonging to CTA, 
members of subgroup II are expressed in various normal adult tissues.   
All proteins of the extended MAGE family share certain homologous regions, 
including the large central region MAGE homology domain (MHD) [Chomez et al., 
2001]. The MHD does not contain any regions of significant homology with other 
known proteins, but it appears to be an important site of protein-protein interaction. 
Various MAGE family members are suspected to play important physiological roles 
during embryogenesis, germ cell genesis and apoptosis. However, the biological 
function and their role in cell activities in both, germ line cells and tumors remain 
poorly understood.  
Despite the common belief that CTA are found in tumor cells mostly as an unspecific 
result of the demethylation process, some studies suggest that the expression of 
CTA such as MAGE could play a role in human tumorigenesis.  
Indeed, recent data indicate that expression of MAGE genes in cancer cells 
contributes directly to the malignant phenotype and response to therapy. In some 
human cells lines, for example, overexpression of at least one of the MAGE-A genes 
correlates with an increased resistance to TNF-mediated cytotoxicity [Park et al., 
2002] or with resistance to the widely used chemotherapeutic drugs Paclitaxel and 
Doxorubicin, which are typical phenomena of aggressive cancer [Glynn et al., 2004].  
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2.6 Aim of the study 
The purpose of this work is to evaluate the potential relevance of Cancer Testis 
Antigen specific immunization to envisage novel types of treatment for Non Small 
Cell Lung Cancer.  
CTA represent interesting tumor associated antigens since next to their limited 
expression to non immunogenic testis cells in normal adult tissues, spontaneous 
specific responses to CTA have been demonstrated in cancer patients.  
To first address the relevance of these TAA in lung cancer, prevalence and 
expression pattern of several CTA were evaluated in surgically excised lung tumor 
specimens of different stages and histology. 
Moreover, the capacity of inducing cellular CD8+ T cell response towards CTA in 
cells from cancer patients was explored. Therefore ex vivo stimulations with        
HLA-A*0101 and HLA-A*0201 restricted epitopes were performed on CD8+ T cells 
infiltrating tumors (TIL). Based on prior data obtained from melanoma TIL, these 
populations were supposed to be enriched in activated specific T cells possibly 
related to specific antigen expression in cancer cells.   
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3 Materials & Methods 
3.1 Reagents and Solutions 
3.1.1 Media & Buffers  
 
 
Complete medium RPMI 1640 + L-Glutamine1 
MEM Non-essential amino acids1 
Hepes buffer 10mM1 
Sodium pyruvate MEM 1mM1 
Glutamax 1mM1 
Kanamycin 100µg/ml1 
HS medium Complete medium 
5% pooled Human serum2 
DMEM-10% FCS DMEM 
10% FCS1 
Kanamycin 100µg/ml   
Glutamax 1mM 
IFNα-DC medium Complete medium 
10% FCS 
IFNα2b (10 000U/ml)3 
50ng/ml GM-CSF4 
IL-4-DC medium Complete medium 
10% FCS 
IL-4 (1000U/ml)5 
50ng/ml GM-CSF 
MACS Buffer PBS* 
0.5% FCS 
EDTA pH 8, 0.5mM6 
 
 
1 GIBCO, Paisley, UK;  2 Blood bank, University Hospital Basel, CH;  3 Intron A, 
Essex Chemie, Luzern, CH;  4 Novartis, Basel, CH;  5 courtesy of Dr. Lanzavecchia, 
Bellinzona, CH;   6 Fluka Chemie, Buchs, CH;  
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3.1.2 Peptides for cellular stimulation 
 
Antigenic peptides were purchased from NeoMPS (Strasbourg, F). 
 
Antigen Sequence HLA-restrict.  Reference 
BMLF-1 GLCTLVAML A*0201 [Steven et al., 1997] 
LMP-2 CLGGLLTMV A*0201 [Murray et al., 1998] 
MAGE-A1161-169 EADPTGHSY A*0101 [Traversari et al., 1992] 
MAGE-A3168-176 EVDPIGHLY A*0101 [Gaugler et al., 1994] 
MAGE-A4230-239 GVYDGREHTV A*0201 [Duffour et al., 1999] 
MAGE-A10254-262 GLYDGMEHL A*0201 [Huang et al., 1999] 
Multi-MAGE-A1 YLEYRQVPV A*0201 [Graff-Dubois et al., 2002] 
NY-ESO-1157-165 SLLMVVITQC A*0201 [Jager et al., 1998] 
 
1
 epitope in common between MAGE-A1, -A2, -A3, -A4, -A6, -A10, -A12. 
 
3.1.3 Primer sets and probes for RealTime PCR 
 
Primers and probes were obtained from Microsynth (Balgach, CH). 
 
Gene Sequence Reference 
β-actin Pre-developed assay 
Applied Biosystem, Foster City, CA 
 
CD4 Assay-On-Demand Hs0018127_m1 
Applied Biosystem, Foster City, CA 
 
CD8α Fwd: CTCGGCCCTGAGCAACTC 
Rev: GGCTTCGCTGGCAGGA 
Probe: ATGTACTTCAGCCACTTCGTGCCGGTC 
this work 
FoxP3 Fwd: GGCACTCCTCCAGGACAG 
Rev: GCTGATCATGGCTGGGCTCT  
Probe: ATTTCATGCACCAGCTCTCAACGG 
[Miura et al., 2004] 
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Gene Sequence Reference 
IDO Fwd: GGTCATGGAGATGTCCGTAA 
Rev: ACCAATAGAGAGACCAGGAAGAA 
Pb: CTGTTCCTTACTGCCAACTCTCCAAGAAACTG 
[Uyttenhove et al., 2003] 
IFN-γ Fwd: AGCTCTGCATCGTTTTGGGTT 
Rev: GTTCCATTATCCGCTACATCTGAA  
Probe: TCTTGGCTGTTACTGCCAGGACCCA 
[Kammula et al., 2000] 
IL-10 Fwd: GTGATGCCCCAAGCTGAGA  
Rev: CACGGCCTTGCTCTTGTTTT  
Probe: CCAAGACCCAGACATCAAGGCGCA 
[Giulietti et al., 2001] 
MAGE-A1 Fwd: TACCTGGAGTACCGGCAGGT 
Rev: TTGGACCCCACAGGAACTCA 
Probe: CGGACAGTGATCCCGCACGCT 
[Riker et al., 2000] 
MAGE-A10 Fwd: CAGGGAGAGCAAGAGGTCAAGA 
Rev: AAGTCCTGCCCACACTCCC 
Probe: CAGCACTGAAGGAGAAGACCTGCCTGTG 
this work 
MAGE-A12 Fwd: TGGCATCGAGGTGGTGG 
Rev: CCCAGGCAGGTGACAAGG 
Probe: TGGTCCGCATCGGCCACTTGTAC 
[Panelli et al., 2000] 
MAGE-A2 Fwd: GACAAGTAGGACCCGAGGCA 
Rev: TGTGGGTCTTCATTGCCCA 
Probe: TGGAGGAGCATTGAAGGAGAAGATCTGC 
this work 
MAGE-A3 Assay-On-Demand Hs00366532 
Applied Biosystem, Foster City, CA 
 
MAGE-A4 Fwd: CCACAGAGGAGCACCAAGGA 
Rev: GCTTTTGCCTGCACTCTTGC  
Probe: AAGATCTGCCTGTGGGTCCCCATTGC  
this work 
NY-ESO-1 Fwd: GCTGAATGGATGCTGCAGA 
Rev: CTGGAGACAGGAGCTGATGGA 
Probe: TGTGTCCGGCAACATACTGACTATCCGA 
[Nakada et al., 2003] 
TNFα Fwd: CCCAGGGACCTCTCTCTAATCA  
Rev: GCTACAGGCTTGTCACTCGG  
Probe: CTGGCCCAGGCAGTCAGATCATCTT 
[Razeghi et al., 2001] 
 
Usually, a 200nM final concentration of each oligo was used. However, in some 
cases concentrations of primers and probes had to be optimized. For MAGE-A12 
mRNA detection final concentrations of reverse primer and probe was adjusted to 
400nM, to 250nM for NY-ESO-1 and 300nM for IFNγ detection. 
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3.1.4 Cell lines 
 
 
CV1 African green monkey, kidney fibroblast ATCC CCL-70 
G401 Human, Wilms’ tumor kidney epithelial cells ATCC CRL-1441 
SK-Mel37 Human, melanoma  
T2 Human, lymphoblast ATCC CRL-1992 
 
 
3.1.5 Plasmids 
For the construction of recombinant virus, three different plasmids were used. These 
plasmids contain two homologous regions from loci I4L, A44L and A56R of the viral 
genome flanking the cloning site [Tsung et al., 1996], in which the different CTA in 
form of endoplasmic reticulum (ER)-targeted minigenes were inserted. Each 
minigene sequence is inserted under the control of a vaccinia specific early promoter 
and transcription termination signals. 
The A44L plasmid contains the full gene encoding human CD80 [Zajac et al., 1998], 
while the full gene encoding CD40 ligand [Feder-Mengus et al., 2005] was cloned 
into plasmid A56R.  
3.1.6 Virus 
Vaccinia virus (Copenhagen strain) was chosen as expression vector. This virus 
belongs to the Orthopox virus gender characterized by an encapsulated double 
strand DNA. Poxviruses replicate in the cytoplasm of a large variety of cells. This 
vector features a strong capacity to express transgenes, a large insertion capacity 
(up to 30kb) and an intrinsic immunogenicity leading to powerful humoral and cellular 
responses [Moss, 1996; Paoletti, 1996]. Only limited virulence and side effects, such 
as cutaneous complications and encephalitis, were reported, following its 
administration.  
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3.2 Cellular immunology techniques 
3.2.1 Cell cultures 
3.2.1.1 Lymphocytes and Monocytes  
PBMC were isolated from heparinized peripheral blood of each patient by          
Ficoll-Hypaque density gradient centrifugation. Monocytes or CD8+ T lymphocytes 
were purified from PBMC or respectively TIL by magnetic bead separation (Miltenyi 
Biotec, Gladbach, D). 
3.2.1.2 Dendritic Cells 
DC were derived from monocytes upon six days culture in DC medium containing 
either GM-CSF and IL-4 or GM-CSF and IFNα. For maturation (→ mDC), 1µg/ml LPS 
(abortus equi, Sigma, Buchs, CH) was added to DC cultures for eight hours before 
pulsing with specific peptides. 
3.2.1.3 EBV-BL 
As restimulation requires autologous antigen presenting cells, EBV-BL lines were 
generated by infecting CD14- cell fraction from patients’ PBMC with Epstein-Barr 
virus containing cell (B95.8) supernatants. 5µg/ml Cyclosporin A (Novartis, Basel, 
CH) were added and infected cells were cultured in complete medium-10% FCS in 
the presence of IL-6 (supernatants from a transfected cell line; courtesy of Dr. 
Lanzavecchia, Bellinzona, CH).   
3.2.2 Tumor Infiltrating Lymphocyte expansion 
Tumor samples were surgically excised and transferred into PBS. In order to obtain a 
cell suspension, tumor samples were mechanically disrupted and incubated over 
night at 37°C in complete medium containing 560µg/m l Collagenase II (Sigma, 
Buchs, CH). After washing the cell suspension, T lymphocyte proliferation was 
stimulated by solid phase bound anti-CD3 (500ng/ml, clone TR66; gift from Dr. 
Lanzavecchia, Bellinzona, CH) and anti-CD28 (100ng/ml; Pharmingen, San Diego, 
CA) on pre-coated plates in HS medium supplemented with 100U/ml IL-2  
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(Hoffmann-La Roche, Basel, CH) for two weeks. Medium was changed twice per 
week. 
3.2.3 CTL induction 
Autologous mDC were pulsed for two hours with 50µg/ml MAGE-A1, -A3, -A4, -A10, 
Multi-MAGE-A, NY-ESO-1 and EBV BMLF-1/ LMP-2 antigenic peptides or infected 
with UV-irradiated recombinant vaccinia virus (m.o.i. 1-3) for 16 hours at 37°C and 
irradiated (3000 rad). Loaded / infected APC were cultured with tumor infiltrating 
CD8+ T lymphocytes (1x10e6 CD8+ and 5x10e5 APC per well) in presence of HS 
medium containing IL-2 at 37°C for ten days by chan ging the medium on day four, six 
and eight. For restimulation, autologous mDC or EBV-BL pulsed with different 
peptides or infected with recombinant virus were used in alternating cycles           
(rVV - soluble peptide - soluble peptide).  
3.2.4 Cytotoxicity test 
CTL function was tested in standard 51chromium release assays using T2 as target 
cell line. After labelling (100µCi/sample) for one hour, T2 cells were pulsed with the 
different specific peptides (10µg/ml) for two hours and added to CTL cells at effector 
to target ratios (ET ratio) of 100:1, 50:1, 25:1, 12.5:1 and 6.25:1. To minimize 
unspecific killing, K562 cells were added to each condition (K562:T2 ratio = 100:1). 
After four hours incubation, supernatants containing released 51Cr were transferred to 
plates precoated with scintillation liquid and read by a luminescence counter. The 
percentage of specific lysis was calculated by the subtraction of spontaneous release 
from sample value divided by the subtraction of spontaneous from maximal release 
value x100. Each assay was performed in duplicate. 
3.2.5 Phenotypic characterization 
For characterization of immunocompetent cells in fresh tumor samples, after 
unspecific proliferation or antigen specific stimulation, cells were stained with 
fluorescent monoclonal antibodies and analysed by flow-cytometry (FACScalibur; 
Becton Dickinson, San Josè, CA) using Cell Quest software (Becton Dickinson). 
FITC or PE labelled anti-CD3, -CD4, -CD8, -CD14, -CD16, -CD45 (Becton Dickinson) 
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were used for tumor samples analysis, while specific CTL were characterized by 
using PE fluorochrome labelled pMHC complexes (pentamers specific for MAGE-A1, 
-A3, -A4, -A10, Multi-MAGE-A and NY-ESO-1, HLA class I restricted epitopes; 
Proimmune, Oxford, UK).  
3.2.6 Immunohistochemistry 
Formalin-fixed paraffin-embedded tumor specimens were processed in the Institute 
of Pathology according to standard methods [Bolli et al., 2002]. Sections were 
stained with the monoclonal antibody 57B for the identification of multiple MAGE-A 
gene products and D8.38 for NY-ESO-1 detection. Both antibodies were previously 
generated and characterized in our lab [Bolli et al., 2002; Kocher et al., 1995; 
Schultz-Thater et al., 2000]. 
The Histoscore was calculated by considering the intensity of the staining (0-3) and 
percentage of the stained tumor areas. Two evaluations of every section were done 
and analysed together. From a minimal Histoscore of 30, meaning a low-intensity 
staining (1) of 30% of cells or high-intensity staining (3) of no more than 10% of cells, 
the staining was considered as positive. Maximal staining reached a Histoscore of 
300 (intensity 3 x area percentage 100).  
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3.3 Molecular biology techniques 
The following methods were applied, if not specifically mentioned, according to the 
general procedures currently adopted in molecular biology [Sambrook et al., 1989]. 
3.3.1 Gene expression evaluation 
For quantification of gene expression, surgical specimens were cut into small pieces 
and frozen in RNAlater at -70°C. After thawing, tum or tissues were mechanically 
disaggregated using the Medimachine System (Becton Dickinson, San Josè, CA). 
RNA was extracted following RNeasy® Mini Kit protocol (Qiagen, Basel, CH) and 
treated with DNase I (Invitrogen, Paisley, UK) before reverse transcription using     
M-MLV RT enzyme (Invitrogen, Paisley, UK). Specific amplification of reverse 
transcribed RNA was performed by quantitative real time PCR using primers and 
probes specific for MAGE-A1, -A2, -A3, -A4, -A10, -A12, NY-ESO-1, CD4, CD8α 
chain, FoxP3, IFNγ, IDO, IL-10, TNFα and β-actin, used as internal reference (see 
above). All assays were run in duplicates and results with a standard deviation >2% 
were excluded. SK-Mel37 melanoma cell line, expressing all CTA genes under 
investigation, was used as positive control for CTA expression. 
Statistical analysis was performed by Statistica software (StatSoft, Tulsa, OK) using 
the Spearman rank correlation or Mann-Whitney’s nonparametric U Test. 
3.3.2 Virus construction 
Recombinant vaccinia viruses were constructed by a two-step procedure. First, 
plasmids containing foreign genes were generated. These genes are controlled by a 
vaccinia virus promoter and flanked by sequences derived from non essential sites 
on the viral genome (see above). Second, the foreign genetic material of the plasmid 
vector was inserted into the viral genome by homologous recombination in vivo 
[Falkner and Moss, 1988]. 
3.3.2.1 Cloning of CTA oligos 
Each CTA oligo cloned into plasmids starts with a sequence encoding the             
ER-targeting signal from the E3-19kD protein of adenovirus. The resulting fusion 
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peptide directly enters the ER, thereby bypassing discrete steps of the class I antigen 
processing pathway.  
Plasmids were digested with restriction enzymes (Promega, Madison, WI)             
Nar I – Apa I (for MAGE-A4, -A3 and NY-ESO-1), Xho I – Nhe I (for MAGE-A2 and 
Multi-MAGE-A), Xho I – Sac I (for MAGE-A1) and BamH I – EcoR I (for MAGE-A10) 
in one or two steps depending on enzyme specific buffer required. After annealing of 
respective CTA oligos the inserts were ligated into the plasmids.  
 
   
I4L
5003 bps
ApaI
NarI
EcoRI
BamHI
NheI
XhoI
I4L r
MAGE-A4
MAGE-A10
MAGE-A2
I4L l
gpt
amp
A44L
5549 bps
XhoI
NheI
NarI
ApaI
A44L r
Multi-MAGE-A
B7.1
NY-ESO-1
A44L l
gpt
amp
 
A56R
5876 bps
XhoI
SacI
NarI
ApaI
A56R l
MAGE-A1
CD40-L
MAGE-A3
A56R r
 
 
Figure 3.1: Maps of plasmids generated in this study. Each plasmid contained two 
regions, homologous of a viral genome locus (I4L, A44L and A56R; illustrated by grey 
boxes), flanking the cloning site. Minigenes MAGE-A2, -A4, -A10 were inserted in 
plasmid I4L. Multi-MAGE-A and NY-ESO-1 were cloned together with full gene CD80 
(B7.1) in plasmid A44L. MAGE-A1 and MAGE-A3 and gene encoding for CD40 ligand 
(CD40-L) were inserted in plasmid A56R (all inserts illustrated by red arrows).             
amp = ampicillin resistance (β-Lactamase); gpt = guanine phosphoribosyl transferase, 
MPA resistance.            
 
 
Competent E. coli (Top 10; Invitrogen, Paisley, UK) were transformed by 
electroporation (25µF and 2.5kV; Gene Pulser apparatus; Bio-Rad Laboratories, 
Hercules, CA) following manufacturers’ protocols and plated on LB agar (GIBCO, 
Paisley, UK) containing 100µg/ml carbenicillin (Fluka Chemie, Buchs, CH). After 
colony selection and amplification of bacteria in LB medium (GIBCO), plasmid DNA 
was isolated using the NucleoSpin® Plasmid Kit (Macherey-Nagel, Oensingen, CH). 
The insert presence was verified on 0.8% - 1% agarose gel (GIBCO) after restriction 
with Bgl I. 
Minigenes encoding MAGE-A2, -A4, -A10 epitopes were inserted into the plasmid 
I4L. Vector A44L was genetically modified with the minigenes encoding              
multi-MAGE-A and NY-ESO-1 epitopes. MAGE-A1 and -A3 epitope coding 
minigenes were inserted into plasmid containing the viral region A56R. 
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3.3.2.2 Transfection into viral vector  
Insertion of the modified VV loci I4L, A44L and A56R into the viral genome was 
obtained after transfection of the plasmid onto infected cells and genetic 
recombination of homologous sequences (crossing-over with I4L, A44L or A56R 
sequence respectively). 
 
       
A44LVV genome 1920001 I4L
Mg-A2 Mg-A10 Mg-A4
NY-1 huCD80 Multi-Mg-A
A56R
Mg-A1 CD40L Mg-A3
 
Figure 3.2: Recombinant vaccinia virus genomic map. Modified VV loci I4L, A44L and 
A56R in viral genome after genetic recombination. Loci I4L and A44L contain minigenes 
encoding for HLA-A*0201 restricted CTA epitopes and full gene huCD80. Minigenes 
encoding for HLA-A*0101 restricted CTA epitopes and full gene CD40L were inserted in 
locus A56R.    
 
 
Briefly, subconfluent adherent CV1 cells were infected with sonicated WT vaccinia 
virus at m.o.i 0.1 for one hour at 37°C. Lipofectam ine™ Reagent (160µg/ml; 
Invitrogen, Carlsbad, CA) and Plasmid DNA (2-5µg) were premixed for 20 minutes at 
room temperature and added to the infection in presence of serum free DMEM 
medium. After four hours of incubation at 37°C DMEM -10% FCS was added to the 
reaction. 
3.3.2.3 Recombinant viral selection 
After complete infection of the cells (about two days), as monitored by cytopathic 
effect (CPE), viruses were harvested, sonicated and used for infection: 100µl of 10-3 
and 10-4 of virus suspension were added to fresh subconfluent CV1 (non transfected 
WT virus served as control). For viral selection a combination of drugs, 25µg/ml 
MPA, 250µg/ml Xanthine and 25µg/ml Hypoxanthine (Sigma, St.Louis, MO), was 
added to the reaction and incubated at 37°C. Only r ecombinant virus expressing the 
enzyme ‘gpt’ can replicate in selective medium. Plaques were picked and 
resuspended in PBS. The selection of recombinant virus required two to four rounds 
with selective pressure and two or three more rounds of plaques selection without 
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pressure which enable the removal of the plasmid sequences containing the 
resistance genes.  
Presence of inserted sequences in the viral genome was verified by conventional 
PCR using oligos specific for the viral flanking regions                                           
(I4L-5’: GGAATAACTCGGATCTGC, I4L-3’: CTATAATAACCAGGAACA;           
A44L-5’: GTTGAAATCTAGTTCTGC, A44L-3’: GAAAGTAAACTATTATGG;       
A56R-5’: ACTCCACAGAGTTGATTGTA, A56R-3’: GTATGTGACGGTGTCTGTAT). 
Expression of inserts was evaluated by antibody staining (CD80 and CD40L) or 
cytotoxicity tests with specific CTL for MAGE-A10 and multi MAGE-A.  
3.3.2.4 Virus amplification and titration 
Virus was amplified by infecting CV1 cells at m.o.i. 0.01 until complete CPE. Cultures 
were then harvested and centrifuged to collect infected cells. While supernatant was 
preserved, cells were resuspended in 10mM Tris pH 8.5, sonicated for one minute 
and centrifuged. Supernatants were pooled and poured onto a cushion of 36% 
sucrose, 10mM Tris followed by ultracentrifugation at 13 000 rpm for one hour. The 
pellet was resuspended in 1mM Tris pH 8.5. 
For titration, dilutions from 1:10e6 to 1:10e9 were performed and CV1 cells were 
infected with 100µl for 24 to 48 hours. Plaques were revealed by crystal violet 
(Sigma, Buchs, CH)/ethanol solution staining of the cell monolayer.  
3.3.2.5 Virus inactivation   
To reduce CPE and prevent replication, viruses were inactivated prior to CTL 
stimulations. Virus solutions were diluted to a final concentration of 5x10e8pfu/ml in 
HBSS (Invitrogen, Carlsbad, CA). 10µg/ml Psoralen (Trioxsalen; Calbiochem, 
Cambridge, MA) was added for ten minutes at room temperature and suspensions 
were exposed to UV light (365nm) for twelve minutes. This photoreaction can 
eliminate a wide range of infectious agents while leaving protein antigens and other 
surface components relatively unmodified [Hanson, 1992]. Expression of genes 
encoded under early viral promoters is not affected. 
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3.4 The procedure at a glance 
From each patient, blood and tumor samples were collected. While evaluation of 
CTA expression was assessed on small pieces of tumor, the bulk of the tissue was 
enzymatically disrupted for TIL isolation. Monocytes and B lymphocytes were 
isolated from patients’ blood for the generation of potent antigen presenting cells. 
Expanded tumor infiltrating CD8+ T lymphocytes were repeatedly stimulated with 
either mature DC or autologous EBV-BL, together with CTA epitopes in form of 
soluble peptides or encoded by a recombinant vaccinia virus developed during this 
study. Specific CTL generation was analysed by phenotypic tests as well as by 
cytotoxic assays.  
  
     
 
Figure 3.3: Illustration of the procedure.  
mDC = mature dendritic cells;   EBV-BL = Epstein-Barr virus-B lymphocytes;               
APC = antigen presenting cells;    TIL = tumor infiltrating lymphocytes;    CTL = cytotoxic 
T lymphocytes;   CTA = Cancer/Testis antigens;   pep = peptides;   rVV = recombinant 
vaccinia virus. 
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4 Patients 
 
From over 70 patients operated during the period April 2003 - May 2006 in the 
Department of Thoracic Surgery of Basel University Hospital, 33 patients with 
NSCLC (mean age 64.3 ± 8.18) were included in this study (Table 4.1). Main 
inclusion criterion was represented by expression of HLA determinants HLA-A*0101 
and HLA-A*0201, restricting CTL responses to the epitopes under investigation.  
 
   
Table 4.1: Clinico-pathological characteristics of patients included in the study.    
LT = lung tumor; AC = adenocarcinoma; LCC = large cell carcinoma; SCC = squamous 
cell carcinoma; n.a. = not available. 
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The majority of tumors were squamous cell carcinomas (17), followed by 
adenocarcinomas (12) and four large cell carcinomas of the lung. Twelve tumor were 
in stage I, nine each in stage II and stage III, and three in stage IV. In 13 patients 
neither lymph node nor distant metastases were evident. 17 patients had lymph node 
but no distant metastases. In the three patients with tumors of stage IV, metastases 
were investigated, since primary tumors at this stage are not routinely resected, 
further explaining the low number of stage IV specimens included in this study.  
Histological grade varied among the tumor specimens with a majority of grade 3 (17), 
13 of grade 2 and only two of grade 1.  
Prior to surgical treatment, five patients underwent neo-adjuvant therapy.  
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5 Results 
5.1 Construction of viral vectors  
Vaccinia viruses are considered as highly attractive vectors for cancer gene therapy. 
Their large genome can be engineered by recombination of multiple genes, which will 
be simultaneously expressed.  
rVVcombi-MAGE contains minigenes encoding HLA-A*0201 restricted epitopes from 
MAGE-A2, -A10 and -A4 in the region I4L. To obtain rVVCGA, supplementary inserts 
encoding for NY-ESO-1 and multi-MAGE-A HLA-A*0201 restricted epitopes together 
with CD80 (region A44L), and for MAGE-A1 and -A3 HLA-A*0101 restricted epitopes 
with CD40L (region A56R), were added to rVVcombi-MAGE. rVVCTA-A1 is a virus 
recombinant in the A56R locus for MAGE-A1 and -A3 epitopes coding minigenes and 
full gene CD40L (Table 5.1). 
  
Recombinant 
viruses 
co-stimulatory 
molecules 
CTA minigenes HLA-
restrict. 
rVVcombi-MAGE huCD80 MAGE-A2,-A4,-A10,multi-MAGE-A, 
NY-ESO-1 
A*0201 
rVVCGA huCD80; huCD40L MAGE-A1,-A2,-A3,-A4,-A10,       
multi-MAGE-A, NY-ESO-1 
A*0101; 
A*0201 
rVVCTA-A1 huCD40L MAGE-A1, -A3 A*0101 
 
Table 5.1: Characteristics of viral constructs. 
 
5.1.1 Genetic characterization of rVV  
DNA insertions were verified by PCR using primers specific for the flanking regions of 
each insert (Figure 5.1). As control, genomic DNA of VVWT, rVVB7.1 and rVV154 was 
used. Amplicons lengths directly depended on each specific construct:  
I4L-MAGE-A2/-A10/-A4 = 529bp 
I4L-WT = 2224bp 
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A44L-NY-ESO-1/huCD80/multi-MAGE-A = 1361bp  
A44L-huCD80 = 1208bp 
A44L-WT = 699bp 
 
A56R-MAGE-A1/huCD40L/MAGE-A3 = 2154bp 
A56R-huCD40L = 1972bp 
A56R-WT = 974bp 
 
 
 
      
     
 
Figure 5.1: Characterization of recombinant viruses: PCR amplification of loci I4L, 
A44L and A56R. Genomic DNA of VVWT (WT), rVVB7.1 (B7.1), rVVCD154 (CD154),  
rVVcombi-MAGE (Combi-Mg), rVVCGA (CGA) and rVVCTA-A1 (CTA-A1) was amplified using 
primers for flanking regions of each insert and analysed in a 1% agarose gel. 1Kb ladder. 
 
 
All three viral vectors displayed the expected genetic profile confirming the presence 
of the recombinant sequences in their genome. rVVcombi-MAGE contains three 
minigenes encoding MAGE-A2, MAGE-A10 and MAGE-A4 epitopes within the I4L 
region, and sequences for NY-ESO-1157-165 and multi-MAGE-A epitopes together with 
human CD80 within the A44L region. In this construct, the A56R region was not 
modified and remains wild type-like, whereas in rVVCGA, which derives from    
rVVcombi-MAGE, minigenes encoding MAGE-A1 and MAGE-A3 epitopes together with 
the gene encoding CD40L were also inserted in this locus. rVVCTA-A1 contains the full 
gene CD80 in the A44L region and sequences for MAGE-A1, MAGE-A3 epitopes 
and CD40L in the A56R region. 
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5.1.2 Evaluation of recombinant genes expression  
The capacity of the three recombinant vaccinia virus generated (rVVcombi-MAGE, rVVCGA 
and rVVCTA-A1) to express human CD80 and CD40L proteins was verified by antibody 
staining of infected cell surfaces followed by flow cytometry analysis. CV-1 cells were 
infected with replicative virus at m.o.i. 1. As control, similar infections were performed 
with VVWT, rVVB7.1 and rVV154 (Figure 5.2).  
 
 
                   
           
Figure 5.2: Cell surface expression of co-stimulatory molecules CD80 and CD40L 
following infection with rVV. CV1 cells were infected with replicative VVWT, rVVB7.1, 
rVVCD154, rVVcombi-MAGE, rVVCGA and rVVCTA-A1 at m.o.i. 1. Phenotypic analyses were 
performed using antibodies specific for human CD80 and CD40L. 
 
 
rVVcombi-MAGE, rVVCGA and rVVCTA-A1 infected cells showed surface expression of 
human CD80 protein comparable to that of the positive control rVVB7.1. Similarly 
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expression of human CD40L was detectable following infection with rVVCGA and 
rVVCTA-A1 and not with rVVcombi-MAGE. CV1 infected with VVWT remained negative for 
either protein. 
The immuno-modulatory activities of the vaccinia-expressed human CD80 and 
CD40L molecules, e.g. the activation of immune cells through CD28 and CD40 
binding, respectively, were previously demonstrated [Feder-Mengus et al., 2005; 
Zajac et al., 1998]. 
 
Viral expression of recombinant CTA minigenes and HLA-A*0201 presentation of 
their products was indirectly tested by measuring the expression of MHC molecule on 
the surface of infected T2 cells. Indeed, due to the lack of peptide transporters (TAP), 
T2 cells are not able to correctly process protein and therefore do not stably express 
MHC-class I on the cell surface. However, since the different CTA epitopes in the 
viral constructs are encoded in form of ER-targeted peptides, these products should 
migrate to the ER irrespective of TAP proteins. After cleavage of the signal moiety, 
peptides might bind the resident empty MHC possibly leading to upregulation of  
HLA-A*0201 expression on T2 cell surface.  
T2 cells were infected over night at m.o.i. 20 with rVVCGA and rVVCTA-A1, rVVcombi-MAGE 
and as control with VVWT. Surface HLA-A*0201 expression was detected by a 
specific antibody and measured by flow cytometry (Figure 5.3).  
 
 
 
 
 
Figure 5.3: Upregulation of 
HLA-A*0201 at the surface of 
T2 cells following CTA 
epitope expression. 
Phenotypic analyses were 
performed following over night 
infection of T2 cells with VVWT, 
rVVcombi-MAGE, rVVCGA and 
rVVCTA-A1 at m.o.i. 20. As 
control, non infected T2 cells 
were stained with HLA-A*0201 
antibody. 
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As compared to the non infected control, T2 cells HLA-A*0201 upregulation was 
detected only upon infection with rVVCGA and rVVcombi-MAGE but not with VVWT nor with 
rVVCTA-A1. Indeed, minigenes of the latter viral construct do only encode HLA-A*0101 
restricted epitopes, whereas T2 cell line is HLA-A*0101 negative. 
Further analysis of virus induced expression of each recombinant MAGE-A epitope 
was tested by sensitising target cells upon infection to killing by specific CTL 
recognizing MAGE-A10 or multi-MAGE-A (Figure 5.4). 
 
         
 
Figure 5.4: Cytotoxicity of CD8+ T lymphocyte cell line specific for MAGE-A10 and 
multi-MAGE-A. As target, T2 cells were infected either with rVVcombi-MAGE or VVWT at 
m.o.i. 10. As positive control, cells were pulsed with 20µg/ml of the corresponding soluble 
peptide. 
 
 
The cytotoxicity activity of CTL specific for MAGE-A10 and multi-MAGE-A against 
rVVcombi-MAGE infected targets confirmed expression of the corresponding epitopes. 
Moreover, levels of epitope presentation were at least comparable to those elicited 
by 20µg/ml soluble peptide pulsing. As expected, VVWT infected T2 cells were 
unaffected by MAGE specific CTL. 
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5.2 Lung Tumor samples characterization 
5.2.1 Cancer Testis Antigens expression 
5.2.1.1 Gene expression  
5.2.1.1.1 Evaluation of the technique 
Analysis of CTA gene expression by real-time qRT-PCR in tumor samples required 
validation of qualitative and quantitative features of the methods employed.  
Following the definition of optimal concentrations for each oligonucleotide set, 
efficacy of qPCR was first evaluated. For this purpose, serial dilutions of cDNA from 
CTA positive cell line SK-Mel37 were tested (Figure 5.5A).  
First, for most CTA, ratio to reference gene β-actin (delta Ct) remained stable up to a 
thousand fold dilution reaching then the limit of detection. A linear correlation 
between β-actin and MAGE expression was observed.  
 
    
 
Figure 5.5: Evaluation of CTA mRNA detection by quantitative real time PCR.         
A: Efficacy of CTA detection. Stability of amplification was tested on diluted SK-Mel37 
cDNA; B: Sensitivity of CTA detection. Gene expression was assessed from RNA mixture 
obtained from SK-Mel37 admixed with G401 cells to different dilutions. 
 
 
Second, the sensitivity of the whole procedure from RNA extraction, reverse 
transcription to quantitative amplification of gene of interest was tested by spiking 
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experiments. CTA positive SK-Mel37 cells were diluted with CTA negative G401 cells 
to a total of 5x10e6 cells. Gene expression of CTA MAGE-A1, -A2, -A3, -A4, -A10,    
-A12 and NY-ESO-1 was measured in every condition (Figure 5.5B). 
Depending on expression level of each gene in SK-Mel37 cells, the procedure of 
RNA purification, cDNA synthesis and PCR amplification enabled the detection of 
CTA positive cells ranging from 50000 cells (1% of total) to 50 cells (0.001% of total) 
for MAGE-A4 and MAGE-A12, respectively. 
5.2.1.1.2 Analysis of NSCLC samples 
Expression of MAGE-A1, -A2, -A3, -A4, -A10, -A12 and NY-ESO-1 genes was 
measured in lung tumor samples. Figure 5.6 illustrates representative CTA 
expression patterns in individual clinical specimens. The expression level of each 
CTA gene varied from negative for all genes (LT1) to high expression levels of few 
(LT20) or several CTA genes tested (LT24). Remarkably, CTA expression level in the 
latter tumor sample was comparable to that detected in the positive control tumor cell 
line SK-Mel37. 
 
   
Figure 5.6: CTA expression patterns from individual NSCLC specimens. CTA 
expression observed in lung tumor samples (LT) was compared to expression in positive 
control cell line SK-Mel37. Expression of individual CTA genes representing less than 
0.1% of β-actin expression was considered as negative.  
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For a better characterization of each tumor sample, CTA gene expression was 
independently evaluated from two pieces of each tumor. The results from both 
measurements were averaged and are represented in Figure 5.7. 
Following the processing and analysis, tumor samples were classified as “CTA 
positive” if gene expression of at least one CTA was >0.1% of β-actin level. The 
quantitative detection of each CTA mRNA resulted in grading the expression from 
“weak” (between 0.1% and 1% of β-actin signal), “moderate” (between 1% and 10% 
of β-actin signal) to “strong” (above 10% of β-actin signal). 
 
           
 
Figure 5.7: CTA gene expression of NSCLC specimens. Upon reverse transcribtion, 
cDNA of MAGE-A1, -A2, -A3, -A4, -A10, -A12 and NY-ESO-1 (NY) was amplified by 
quantitative real time PCR. Two individual samples were investigated for each specimen; 
data illustrate the mean of both measures. AC = adenocarcinoma; LCC = large cell 
carcinoma; SCC = squamous cell carcinoma; LT = lung tumor.  
 
 
In total, 15/33 samples were CTA positive (45%). At least one CTA gene was 
expressed in 5/12 adenocarcinomas (42%), 2/4 large (50%) and 8/17 squamous cell 
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carcinomas (47%). In particular, MAGE-A12 and MAGE-A10 were the most 
frequently expressed CTA genes with 12/15 and 10/15 cases, respectively.           
NY-ESO-1 was only expressed in 4/15, MAGE-A1 and MAGE-A4 genes in 6/15 
positive samples. In most cases, multiple CTA were concomitantly expressed. In 
10/15 positive tumor samples including 3/5 adenocarcinomas, 2/2 large and 5/8 
squamous cell carcinomas, expression of at least four CTA genes was detected.  
5.2.1.2 Protein expression 
Immunohistochemical studies were performed in 19/33 NSCLC samples in order to 
detect CTA protein expression. Our group previously developed two antibodies, 57B 
and D8.38, recognizing several MAGE-A proteins (MAGE-A1, -A2, -A3, -A4, -A6 and 
-A12; [Rimoldi et al., 1999]) and NY-ESO-1, respectively. 
The results obtained by staining tumor sections with these antibodies were graded, 
taking into account the intensity and the area percentage of the staining, according to 
a histoscore (see materials & methods, 3.2.6). 
 
                   
 
Figure 5.8: Immunohistochemical detection of CTA protein in NSCLC. Tumor 
sections were stained with antibodies 57B, specific for MAGE-A1, -A2, -A3, -A4, -A6 and 
-A12 proteins, and D8.38, specific for NY-ESO-1 protein. A = no CT protein expression;  
B = strong MAGE-A protein staining (histoscore 300), but negative for NY-ESO-1 protein; 
C = strong expression of MAGE-A and NY-ESO-1 proteins (histoscore 300 for both 
stainings). 
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14 out of 19 NSCLC sections tested were positive for MAGE-A staining whereas for 
five specimens, the histoscore was below 30 and were therefore classified as 
negative. NY-ESO-1 protein was detected in six sections only. In 2 of 19 tumor 
samples (LT14 and LT24) the maximum histoscore of 300 was detected for MAGE-A 
as well as for NY-ESO-1 proteins. 
A large heterogeneity of MAGE-A and NY-ESO-1 protein expression was detectable 
in the majority of specimens. Expression was frequently focal and limited to defined 
tumor areas. This heterogeneity was even visible within relatively small areas, where 
strongly stained cells were detected close to negative cells (Figure 5.9).  
   
 
Figure 5.9: Heterogeneity of expression. Tumor section stained with antibodies 57B 
and D8.38. For both MAGE-A and NY-ESO-1, intensity of protein expression displays 
strong variation from cell to cell within observed tumor area.  
 
 
5.2.1.3 Correlation gene/protein expression level 
PCR results of CTA genes average expression levels were evaluated in comparison 
with those obtained at the protein level by immunohistochemistry, performed on 
tumor sections. Overall, these techniques did generate matching results except in a 
few cases (Figure 5.10).  
MAGE-A expression was detected in 14 of 19 NSCLC specimens tested, at gene as 
well as at protein level. In one case, immunohistochemistry was negative in the 
presence of a weak MAGE-A12 gene expression (LT11). In LT32, although no CTA 
gene expression was observed, a weak MAGE-A specific staining was detectable. 
Similarly, positivities for NY-ESO-1 were detected by immunohistochemistry in two 
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samples where PCR were negative. However, in both cases, staining was focal with 
a low histoscore (≤60) (LT8 and LT13).  
 
                   
 
Figure 5.10: Comparison of CTA gene and protein expression in NSCLC 
specimens. CTA gene expression was evaluated by quantitative real time PCR, protein 
expression by immunohistochemistry (IHC). Only specimens investigated by both 
techniques are illustrated. AC = adenocarcinoma; LCC = large cell carcinoma;            
SCC = squamous cell carcinoma; LT = lung tumor; NY = NY-ESO-1.  
 
 
 
5.2.1.4 CTA expression related to Tumor Stage and Grade 
Expression of CTA genes in tumors is often thought to be related to their advanced 
stage or histological grade [Bolli et al., 2002; Gure et al., 2005]. Therefore, this 
correlation was evaluated in the NSCLC samples involved in this study. 
Relative intensity of CTA expression, as detected by PCR, was graded based on the 
number of genes expressed and their relative expression level in each tumor 
specimen. Intensity of expression varied from 0 = absent or below threshold to          
1 = weak, 2 = moderate, or 3 = strong. Maximum theoretical value of this index is 21, 
corresponding to a strong expression of all seven CTA under investigation. Thus,  
SK-Mel37 has a relative intensity of CTA expression of 17. 
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Considering all NSCLC specimens tested in this study (n=33), expression of CTA 
appeared to increase with tumor stage (Figure 5.11) although not reaching statistical 
significance due to high standard deviations. The majority of stage I tumors poorly 
expressed CTA (mean score = 1.67). The mean score value of CTA expression in 
stage II was twice as high (mean score = 3.11), and continued to increase in stage III 
tumors (mean score = 4.56). Remarkably, no CTA expression was detected in any of 
the three stage IV tumors. Of note, these samples refer to metastases only, as 
opposed to primary lung tumors sampled in the other stages.  
 
        
 
Figure 5.11: CTA expression related to stage and grade of NSCLC specimens. 
Relative intensity of CTA expression was graded based on the number of genes 
expressed and their relative expression level in each specimen. left: Tumor stage. Mean 
score values (x) of stage I = 1.67±2.8, stage II = 3.11±4.6, stage III = 4.56±5.1,         
stage IV = 0;  right: Tumor grade. Mean score values (x) of grade 1 = 0,                    
grade 2 = 4.08±4.75,  grade 3 = 2.12± 3.66.  
 
 
Regarding tumor grade, no correlation was observed with expression of CTA from 
the NSCLC specimens under investigation. Relative intensity of CTA expression was 
highest in tumors of grade 2 (mean score = 4.08), while 13/17 grade 3 tumors were 
only poorly expressing CTA (mean score = 2.12). The two specimens of grade 1 
were negative for CTA expression. 
5.2.2 Lymphocyte infiltration 
Characterization of lymphocytes infiltrating the tumors was performed by flow 
cytometry. After disruption of tissues by mechanical and enzymatic treatments, cells 
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were labelled with antibodies specific for CD3, CD4, CD8, CD14, CD45 and 
CD16/56. In general, numbers of lymphocytes detected in NSCLC samples were 
small. Only a minority of cells expressed the T cell marker CD3 (on average <2.5% of 
total cells). Accordingly, CD8+ and CD4+ cells were detectable in small percentages 
(0.7±0.8% and 0.17±0.09%, respectively). Monocytes/macrophages (CD14+) and NK 
cells (CD16/56+) represented on average 0.2% of total cells.  
Whereas phenotypic characterization could not be systematically performed, 
presence of T cells was also determined by quantitatively measuring the expression 
of CD4 and CD8 genes in total RNA from tumor samples of different stages and 
grades (Figure 5.12).  
 
        
Figure 5.12: CD4+ and CD8+ T cell infiltration related to stage and grade of tumor. 
CD4 gene expression; CD8 gene expression.  
 
 
Expression of both CD4 and CD8 genes was detected in tumors of all stages with 
similar intensity. Comparatively, higher expression of these markers was found in 
stage IV tumor samples, although these data resulted from three metastatic 
specimens only. No significant correlation with tumor grade was observed. 
To preliminarily assess the activation status of TIL from NSCLC, expression of the 
gene encoding IFNγ was tested by qPCR. IFNγ transcripts could indeed be amplified 
from the majority of specimens, however, the level of expression only exceeded 0.1% 
of β-actin gene expression in five out of 32 cases.  
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5.3 Cytotoxic T lymphocytes  
One of the aims of this study was the detection / generation of CTA specific CTL from 
TIL. Thus, tumor infiltrating CD8+ cells needed to be purified, characterized and 
specifically stimulated. However, due to their limited amount in fresh samples, a 
direct measurement of CTA specific immune response could not be performed. Thus, 
TIL were unspecifically expanded prior to antigenic stimulation. 
5.3.1 Expansion 
TIL expansion was performed by antibody mediated CD3/CD28 triggering in the 
presence of IL-2. After ten days, the T cell fraction represented up to 95% of the 
cultured cells (Figure 5.13, panel A). Average data from the samples under 
investigation are reported in figure 5.13, panel B. In seven cases, TIL could not be 
amplified due to contamination. 
 
 
  
 
Figure 5.13: TIL population before and ten days after non specific expansion.  
A: Example of phenotypic characterization with specific antibody for CD3+ cells.            
B: Phenotypic average from 33 NSCLC specimens. 
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Expanded cell populations included a majority of CD4+ (68±13%) and a substantial 
percentage of CD8+ cells (26±11%). NK cells and monocytes percentages remained 
modest (<3% of total expanded population) (Figure 5.14). 
Importantly, expanded cells represent a selected population out of original tumor 
infiltrating lymphocytes. 
 
 
    
 
Figure 5.14: Characterization of TIL after non specific expansion. Cells were stained 
using specific antibodies for CD3, CD4, CD8, CD14, CD45 and CD16/56. Analysis was 
performed on gated population (figure left). 
 
 
Non specifically expanded CD8+ T lymphocytes were phenotypically characterized 
for CTA specificity. Staining with multimers specific for CTA peptides was barely 
detectable. Even when the tumor expressed the antigens under investigation, TIL did 
not seem to be particularly enriched in specific CTL. 
5.3.2 Specific CTL induction 
Testing the CTA specificity and the cytolytic potential of CD8+ effector cells purified 
from expanded TIL populations required repeated specific in vitro stimulations with 
autologous mature dendritic cells (mDC). These stimulations were performed using 
either two (MAGE-A1 and -A3, HLA-A*0101 restricted), four (MAGE-A4, -A10,    
multi-MAGE-A and NY-ESO-1, HLA-A*0201 restricted) or six epitopes (MAGE-A1,     
-A3, -A4, -A10, multi-MAGE-A and NY-ESO-1), depending on patients’ HLA type.  
Out of 26 expanded TIL populations, 15 were stimulated with autologous APC pulsed 
with CTA derived soluble peptides. The other eleven CD8+ lymphocyte populations 
were stimulated with APC alternatively infected with rVVcombi-MAGE or pulsed with 
peptides. In six of them both protocols were comparatively evaluated. 
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Figure 5.15: CTL response detection / generation in NSCLC upon specific in vitro 
stimulation. CTA specific CTL from expanded CD8+ T lymphocytes infiltrating the tumor 
specimens (LT) stimulated with mature IL-4-DC and specific CTA epitopes in form of 
soluble peptides or encoded by minigenes in rVV. NY = NY-ESO-1. 
 
 
Out of a total of 104 CD8+ cultures restimulated up to five times with CTA, in ten from 
seven different patients a significant specific lysis (>10% at 50:1 ET ratio) was 
detected (Figure 5.15). 
In six of ten cultures, only a minor cytotoxic activity not exceeding 20% at 50:1 ET 
ratio was observed. In three antigen stimulated cultures, specific CTL response 
ranged between 20% and 40% specific lysis (at 50:1 ET ratio). Representative 
examples of minor and negative epitope specific cytotoxicity are reported in        
figure 5.16. 
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Figure 5.16: CTA specific cytotoxic activity of CD8+ T lymphocytes infiltrating 
NSCLC. Following three and four boosts with HLA-A*0201 restricted CTA epitopes 
(example with MAGE-A4 and NY-ESO-1, LT19) specific target lysis was assessed by 
51chromium release assays. Cytotoxic activity of less than 10% specific lysis at 50:1 ET 
ratio was considered as negative. 
 
 
However, in these nine cultures, despite several specific stimulations, CTA specific 
multimer staining of effector cells remained below 0.5%, as illustrated in figure 5.17. 
 
 
           
   
Figure 5.17: Phenotypic analysis of tumor infiltrating CD8+ T cells after specific 
stimulation with CTA epitopes. After each specific stimulation with CTA epitopes 
(example with MAGE-A4 and NY-ESO-1, LT19) CD8+ T lymphocytes were stained with 
corresponding MHC-multimers and CD8 specific antibodies.  
 
 
Results 
 
 
50 
However, following stimulation of CD8+ TIL from NSCLC patient LT24, a strong 
specificity for one of the CTA under investigation could be observed. While upon anti 
CD3/CD28 non antigen specific stimulation only 0.4% of CD8+ cells displayed the 
MAGE-A10 HLA-A*0201 phenotype as detected with specific multimers, this small 
population became a much larger fraction of CD8+ T cells (>35%) following antigen 
stimulation. A corresponding cytotoxic activity exceeding 60% specific lysis at 50:1 
ET ratio was observed following only three stimulations of TIL (Figure 5.18).  
 
 
   
 
Figure 5.18: MAGE-A10 specific CTL characterization of specimen LT24.                
A: MAGE-A10 effector T cells phenotype before and after specific stimulations. CD8+ 
cells were stained with MAGE-A10 multimer. B: Cytotoxic activity of CTL following three 
stimulations with MAGE-A10 antigenic epitopes. Specific lysis was assessed by 
51chromium release assay. 
 
 
 
5.3.2.1 Use of rVV for specific CTL stimulation 
Comparative studies on the efficacy of antigenic stimulation with the viral vector 
versus soluble peptides were performed in six NSCLC patients. In 21/24 cultures 
CTA specific CTL response was undetectable. In one case cytotoxicity was only 
generated upon soluble peptide stimulation, whereas in the remaining two,       
MAGE-A10 and NY-ESO-1 specific responses were only observed in the virus 
stimulated cultures (Figure 5.19). 
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Figure 5.19: Comparative 
stimulations of CD8+ T lymphocytes 
using either soluble peptides or 
rVVcombi-MAGE as immunogenic 
reagents. CD8+ T cells stimulated with 
mDC either only pulsed with soluble 
peptides (example with MAGE-A10 
and NY-ESO-1, LT18), or in alternating 
cycles pulsed and infected with    
rVVcombi-MAGE encoding the respective 
epitopes. Cytotoxicity was tested after 
five stimulations by 51chromium 
release assay. 
 
 
 
 
Interestingly, the high CTL specificity against MAGE-A10 observed in CD8+ T cell 
population of LT24 (Figure 5.18) had been primed by rVV infected APC. 
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5.4 Parameters influencing CTL detection/generation 
All in all, despite several stimulations using strong APC and immunogenic reagents, 
detection / generation of CTA specific CTL from expanded TIL populations of NSCLC 
was extremely rare. To obtain an insight into this lack of cellular immune 
responsiveness, several parameters of the tumor micro-environment possibly 
influencing CTL presence or activation, were investigated. 
5.4.1 Expression of CTA  
The use of tumor infiltrating lymphocytes for the detection of CTA specific CTL is 
based on the assumption that these CTL are enriched in the environment where the 
antigens are expressed. However, comparison of specific CTL with the expression of 
corresponding CTA in the original tumor specimens demonstrated no obvious 
correlation (Figure 5.20). 
 
 
    
Figure 5.20: Overview of CTA expression and immune responses obtained from 33 
NSCLC specimens. LT = lung tumor; AC = adenocarcinoma; LCC = large cell 
carcinoma; SCC = squamous cell carcinoma; IHC = immunohistochemistry;                  
NY = NY-ESO-1. 
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In four of 15 tumor specimens expressing CTA, TIL could not be expanded and 
therefore evaluation of immune response was not possible. 
Among the seven patients showing evidence of CTL response, LT24 emerged not 
only in terms of CTA expression level, but also in terms of expression pattern. 
Indeed, MAGE-A10 was highly expressed in the original tumor, while the tumors of 
the other six patients either did not express any CTA or not those targeted by the 
CTL generated in vitro. 
Thus, results obtained from these 15 CTA positive NSCLC specimens did not 
obviously confirm the hypothesis of a CTA specific CTL enrichment in TIL. 
5.4.2 Evaluation of Immunocompetence of CD8+ TIL 
In order to attempt an assessment of the overall immunocompetence of TIL from 
NSCLC, infiltrating CD8+ cells were stimulated with two HLA-A*0201 restricted 
epitopes from the respiratory Epstein-Barr virus (EBV; epitopes derived from BMLF-1 
and LMP-2 proteins). Following non antigenic CD3/CD28 expansion in vitro, specific 
CTL could easily be induced, as detected by both phenotypic and cytotoxic assays 
(Figure 5.21).  
   
  
Figure 5.21: Antiviral CTL response from expanded TIL. CD8+ T cells (LT19) were 
stimulated with mDC pulsed with EBV derived epitopes. A: Phenotypic characterization 
after three and four boosts. Cells stained with CD8 specific antibodies and BMLF-1 and 
LMP-2 multimers; B: CTL sensitisation measured by cytotoxicity assay after three and 
four boosts.   
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However, these results per se do not exclude the presence of immunomodulatory 
factors in the tumor micro-environment possibly impairing local responses.  
5.4.3 Immunomodulatory factors in freshly excised tumors 
The expression of genes encoding factors playing a critical role on the activation 
status of effector cells was evaluated by qRT-PCR in a number of freshly excised 
tumor tissues (n=21). Among factors which might inhibit CTL generation, expression 
of FoxP3, IDO and IL-10 genes was measured and correlated with expression of 
IFNγ and TNFα genes, suggestive of an activated status of resident TIL. For each 
NSCLC specimen, levels of potential modulatory factors were put in relation with CTL 
generation or CTA expression.   
5.4.3.1 Markers of activation 
In situ activation of CD8+ T cells might represent a marker suggesting a capacity to 
generate specific CTL. Interestingly, expression of the key T cell activation marker 
IFNγ gene was found to correlate with CD8 gene expression level in the NSCLC 
samples tested in this study (Figure 5.22).  
 
 
       
 
 
 
Figure 5.22: Correlation of CD8 gene 
expression with IFNγ gene expression. RNA 
expression profiles of tumor specimens (n=21) 
were analysed by nonparametric Spearman’s 
correlation test; r = 0.62.  
 
 
 
Thus, to evaluate if the activation status of CD8+ T cells might have affected their 
capacity to generate specific CTL, IFNγ/CD8 ratios were studied in TIL yielding or not 
specific CTL upon repeated in vitro stimulations.  
The mean ratio of IFNγ/CD8 in TIL from which no CTA specific CTL could be raised 
was three times lower than the one from the lymphocyte populations, where CTA 
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specific immune responses could be generated (Figure 5.23). A significant 
correlation between IFNγ/CD8 ratio and CTL generation was thus detectable           
(p = 0.022).  
 
 
 
 
 
 
Figure 5.23: IFNγ/CD8 ratio from NSCLC 
specimens, grouped according to their 
capacity to generate specific CTL 
responses. Ratios were compared using 
Mann-Whitney’s nonparametric test. Significant 
correlation, p = 0.022. 
 
 
 
Importantly, the highest value observed in specimens with specific CTL responses 
(0.25) corresponds to sample LT24, which is the only one where CTL response is 
specific for a CTA expressed by the tumor.  
 
 
TNFα is an important maker of local inflammation and immune activation. 
Interestingly, within the tumor samples tested in this study expression of TNFα gene 
is significantly lower than that detectable in healthy lung tissue (p = 0.025)        
(Figure 5.24). However, data obtained from different specimens did not support a 
correlation with CTL response nor with presence or absence of CTA.  
 
 
 
 
 
 
 
Figure 5.24: TNFα expression in NSCLC 
specimens and healthy lung tissue 
specimens. Mann-Whitney’s nonparametric 
test; significant correlation, p = 0.025. 
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5.4.3.2 Markers of local cellular immune response inhibition 
As compared to healthy lung tissue (n=8), genes encoding inhibitory factors such as 
IDO and IL-10 were overexpressed in freshly excised NSCLC specimens         
(Figure 5.25).  
 
       
Figure 5.25: Overexpression of IDO and IL-10 in NSCLC specimens compared to 
healthy lung tissue specimens. Marker gene expression is relative to β-actin gene 
expression. Mann-Whitney; significant correlation for IDO, p = 0.022 (IL-10, p = 0.088). 
 
 
These markers have been suggested to impair tumor surveillance by inhibiting the 
generation of CTL activity. Similarly, expression of FoxP3 gene, as a marker of 
regulatory T cells known to inhibit proliferation of effector cells, was analysed. 
No specific negative correlation could be observed for any of the inhibitory markers 
(Figure 5.26). In addition, the level of IFNγ/CD8 ratio in the specimens was not found 
to be influenced by these factors.  
 
   
Figure 5.26: Expression of inhibitory factors in NSCLC specimens: comparison of 
tumors from which CTA specific CTL responses were generated or not. Each 
marker gene expression is relative to the expression of β-actin gene.  
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Despite the correlation between CTA expression and poor survival [Gure et al., 2005] 
and the trend linking stage and CTA also observed in this study, a relation between 
IDO, IL-10 or FoxP3/CD4 and CTA presence could not be observed for the NSCLC 
specimens under investigation.  
5.4.4 Origin and number of CD8+ cells  
One of the aims of this study was to demonstrate that the generation of specific CTL 
responses in NSCLC patients is possible, given an appropriate set of immunogenic 
reagents. 
However, relatively small numbers of lymphocytes were initially obtained from the 
tumors, implying a limited diversity of antigen recognition. Moreover, despite 
demonstration of immunocompetence of TIL for viral antigens, limited CTA specific 
CTL generation was obtained, without correlation in 9/10 cases to CTA expression. 
On the other hand, the frequency of naive CTL specific for CTA is known to be low in 
PBL from healthy donors (in the range of 1 per 10e7 to 1 per 10e6 CD8+ T cells; 
[Chaux et al., 1998]). These findings may indicate that numbers of CD8+ cells 
purified from tumor specimens were not adequate to generate CTA specific CTL 
responses. 
Thus, in order to attempt to increase the size of the CD8+ T cell pool, induction of 
CTA specific CTL was investigated on CD8+ peripheral blood lymphocytes obtained 
from patients bearing CTA expressing tumors as well as from healthy donors. CTA 
specific stimulations were performed in cultures including a minimum of 3x10e6 
CD8+ cells and 1x10e6 APC per condition. 
5.4.4.1 PBL from healthy donors 
Peripheral blood isolated CD8+ cells from four different healthy donors (HD) were 
stimulated with CTA peptide pulsed IFNα-DC. These cells were recently shown to 
provide APC functions comparable to mDC [Lapenta et al., 2006]. 
In three out of four donors, CTA specific CTL were detected after two to four 
stimulations. Remarkably, in all of them specificity against MAGE-A10 epitope was 
induced. In one case, as shown in figure 5.27, MAGE-A10 specific multimer staining 
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was detected in nearly 27% and 50% of CD8+ population after only two and four 
stimulations respectively.  
 
   
 
Figure 5.27: MAGE-A10 specific CTL generation following multiple specific 
stimulations. Peripheral blood CD8+ lymphocytes of healthy donors stimulated with 
MAGE-A10 peptides pulsed autologous IFNα-DC. Phenotypic characterization of CD8+ 
cells with MHC-multimer specific for MAGE-A10. 
 
 
In addition to MAGE-A10, CTL specific for multi-MAGE-A and NY-ESO-1 epitopes 
were generated in two out of three cultures (Figure 5.28). While, after five 
stimulations, 30% of CD8+ T cell population was multi-MAGE-A specific, positivity for 
NY-ESO-1 multimers pertained to 7% only of CD8+ T cells after six stimulations.  
 
 
        
        
 
Figure 5.28: multi-MAGE-A and NY-ESO-1 specific CTL generation after multiple 
specific stimulations. Peripheral blood CD8+ lymphocytes of healthy donors stimulated 
with multi-MAGE-A or NY-ESO-1 peptides pulsed autologous IFNα-DC. Phenotypic 
characterization of CD8+ cells with corresponding MHC-multimers.  
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The effector function of these MHC-multimer positive populations was confirmed by 
standard chromium release assays. Strong cytotoxicity activity was detected in all 
these cases except in the NY-ESO-1 specific cell culture (Figure 5.29).  
 
    
Figure 5.29: Functional analysis of CTL specific for MAGE-A10, multi-MAGE-A and 
NY-ESO-1. Peripheral blood CD8+ lymphocytes of healthy donors specifically stimulated 
for three (MAGE-A10), respectively five (multi-MAGE-A and NY-ESO-1) times. 
Cytotoxicity was measured by 51chromium release assay. 
 
 
Despite the successful CTL generation with MAGE-A10, multi-MAGE-A and          
NY-ESO1 epitopes, generation of specific CTL against MAGE-A4 failed in all four 
attempts with HD-PBL. As illustrated in figure 5.30, regardless of the number of 
stimulations with respective antigenic peptide, multimer detection of MAGE-A4 
specific CD8+ cells remained negative. Likewise, no specific cytotoxicity against 
MAGE-A4 was detectable.  
 
     
   
Figure 5.30: Phenotype and functional analysis of CD8+ cells after multiple    
MAGE-A4 specific stimulations. Peripheral blood CD8+ lymphocytes of healthy donors 
stimulated with MAGE-A4 peptides pulsed IFNα-DC. A: Flow cytometric analysis of 
MAGE-A4 CD8+ cells stained by MAGE-A4 multimers. B: Cytotoxicity analysis by 
51chromium release assay. 
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5.4.4.2 PBL from patients 
Accordingly, in two NSCLC patients, peripheral blood CD8+ lymphocytes were 
isolated and stimulated with epitopes from CTA expressed in the tumor              
(multi-MAGE-A and MAGE-A10). As APC, either peripheral blood CD14+ cells 
directly, CD14+ derived IFNα-DC or tumor derived fibroblasts were used. 
No responses against multi-Mage-A or MAGE-A10 could be observed in these 
patients. 
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6 Discussion  
 
In contrast to other tumors such as melanoma, in lung cancer relevant 
immunologically dominant antigens remain unknown.  
The ideal target antigen for cancer vaccines should be highly immunogenic, be 
expressed at a high level in tumor tissue, optimally by all malignant cells, and not or 
only at low levels in normal tissues.  
Cancer/testis antigens represent interesting targets because of their highly restricted 
expression patterns in normal tissues [Chen and Old, 1999; Simpson et al., 2005] 
and their expression in a wide range of different human tumor types [Juretic et al., 
2003]. Apparently, the expression levels vary between malignant tissues. Importantly, 
they have been found to be frequently expressed in non small cell lung cancers 
[Fischer et al., 1997; Weynants et al., 1994]. In addition, CT antigens such as       
NY-ESO-1 may be spontaneously immunogenic, inducing an integrated response 
involving both cellular und humoral arms of the immune system [Korangy et al., 
2004]. 
These data led us to comparatively investigate in this work CTA expression in 
NSCLC and the capacity to induce a specific immune response in non vaccinated 
patients. 33 tumors with different histologies, stages and grades were studied. 
Inclusion criteria was the expression of A*0201 or A*0101 HLA alleles.  
 
CTA expression was measured at gene level and confirmed at protein level. We 
observed frequent expression of CTA in squamous cell, adeno- and large cell 
carcinoma of non small cell lung cancer specimens. Nearly half of all tumor samples 
tested expressed at least one of MAGE-A or NY-ESO-1 antigens. Moreover 
expression was equally distributed in the three histological subtypes. Other works, 
however, described a more frequent CTA expression in squamous cell carcinoma as 
compared to other subtypes [Grunwald et al., 2006; Peikert et al., 2006].  
CTA gene expression was not observed to increase with tumor grade. However, a 
trend could be detected regarding the stage, which depends on size and metastatic 
characteristics but not on differentiation status of primary tumor. This may remind 
previous works where expression of these antigens was shown to correlate in 
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NSCLC with poor prognosis [Bolli et al., 2002; Gure et al., 2005]. The inherent 
variability of expression and the relatively small number of specimens involved in this 
study might explain the poor correlation found in the 33 NSCLC specimens under 
investigation. 
 
Protein detection data revealed that in many tumor tissues, CT antigens are not 
found to be expressed by all tumor cells. This phenomenon of focal expression was 
already observed in other carcinomas [Bolli et al., 2002; Chitale et al., 2005; Sarcevic 
et al., 2003]. Clearly, in this context, complete destruction of the whole malignant 
tissue by CTL of a single specificity might appear unrealistic. However, the 
occurrence of local antigen spreading may compensate the limitations of the initial 
immune response. This phenomena may lead to the activation of different CTL 
specificities by antigens released by tumor cells killed by the vaccine specific T cells 
[Ma et al., 2004; Vanderlugt and Miller, 2002].  
As previously described for CTA [Gure et al., 2005], concomitant expression of 
multiple MAGE-A and NY-ESO-1 genes was frequently detected within the same 
specimen, suggesting the use of polyvalent CT antigen specific vaccines in 
subgroups of NSCLC patients [Chianese-Bullock et al., 2005]. By targeting various 
CTA, the number of eligible patients can be increased. Furthermore, a vaccination 
against multiple CT antigens simultaneously expressed in tumors might decrease the 
risk of tumor escape from the immune system, through the loss or down-regulation of 
single target antigens.  
 
Recently, MAGE-A4 was shown to be involved in the positive regulation of apoptosis, 
thus, potentially acting as a tumor suppressor protein [Peikert et al., 2006]. 
Overexpression of this CTA may sensitize malignant cells to apoptotic triggering by 
chemotherapeutical agents. Remarkably, MAGE-A4 was one of the least expressed 
antigens detectable among the seven CTA tested in this study.  
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Spontaneous regression of tumors without therapy and the heterogeneity of clinical 
progression of disease among patients with the same histologic  malignancy suggest 
the existence of pre-sensitization of the immune system, possibly induced by tumor 
cells, playing a role in the clinical course of the disease [Shankaran et al., 2001]. 
Thereby, a strong incentive to the development of vaccination protocols, able to 
boost immune responses for therapeutic purposes in defined types of cancer, may be 
provided.  
Clinical trials based on the administration of synthetic peptides or recombinant 
proteins suggest that specific T cells can indeed be induced by immunization 
[Atanackovic et al., 2004; Morse et al., 2005; Thurner et al., 1999]. Thus, for the first 
time, our study systematically investigated whether CTL recognizing specific CTA 
epitopes could be expanded from lymphocytes infiltrating NSCLC in non vaccinated 
patients.  
 
Classical TIL expansion protocols were updated by using mitogenic anti-CD3 and 
anti-CD28 after collagenase digestion of tumor specimens. However, numbers of 
lymphocytes infiltrating the tumor were relatively low before non specific expansion, 
thus providing a limited repertoire for generation of CTA CTL. No correlation of T cell 
infiltration with tumor stage or grade could be observed. After non specific expansion, 
CTL responses were undetectable in tumor infiltrating lymphocytes. Several 
stimulations were performed using peripheral blood monocytes derived dendritic cells 
pulsed with soluble antigen or infected with a recombinant viral vector developed 
during this study.  
CTA specific T cell stimulation was induced using mature DC as APC [Salio et al., 
2001; Thurner et al., 1999]. Many clinical trials are addressing the feasibility and 
safety of tumor antigen loaded DC, as they are known to be highly effective APC. 
Upon stimulation with maturation factors such as inflammatory cytokines or 
stimulation via CD40 or toll-like receptors, DC upregulate MHC and adhesion 
molecules as well as costimulatory molecules thereby becoming terminally 
differentiated stimulators of T cell immunity [van Kooten and Banchereau, 1997].  
CTA epitope specific CTL were only detected in a few expanded TIL populations, and 
cytotoxicity was usually weak and not complemented by specific multimer staining. 
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These observations suggest that the effector cells were possibly endowed with low 
functional avidity [Dutoit et al., 2002]. Furthermore, in the original tumor specimens, 
either no CTA was expressed (4/7 cases) or some CTA were indeed expressed, but 
not those encoding the specifically recognized epitopes (2/7 cases).  
In one case, however, a high level of CTA specific CTL response was concomitantly 
detectable by cytotoxicity assays and multimer staining. MAGE-A10 gene encoding 
the target epitope was highly expressed in the original tumor, and MAGE-A specific 
staining was evident in a large majority of tumor cells.  
 
Although among the few responses detected from TIL only one was against a CTA 
actually expressed in the same tumor, self antigen expression may influence the 
activation status of cytotoxic cells. Indeed in the CTL positive cases of this study, 
IFNγ level as related to CD8 gene expression was significantly higher when CTA 
were expressed. In the single case of high cytotoxic response, IFNγ/CD8 ratio was 
higher then that detectable in the other samples.  
Still unclear is whether this constellation of data relates to immuno-editing of the 
antigenic phenotype of the tumors by specific CTL responses [Dunn et al., 2004] or if 
the detection of weak specific cytotoxicity could rather be attributed to primary in vitro 
sensitization. However, high CTA specificity detected in the one NSCLC specimen 
was most likely pre-existing and not in vitro induced.   
 
In contrast to specific CTL induction frequently detected in melanoma TIL after 
stimulation with differentiation antigens [Spagnoli et al., 1995], in the present study, 
the majority of TIL populations of CTA positive NSCLC was unable to generate 
specific CTL responses despite repeated stimulation with a panel of well defined 
peptides and highly effective APC. These data suggest that specific CTL 
sensitization in NSCLC is not frequent. Importantly, efficient expansion of CTA 
specific CTL in vivo, has been shown to require long immunization courses [Coulie et 
al., 2001; Thurner et al., 1999].  
In a number of previous reports frequency of CTL precursors specific for a CTA 
epitope has been shown to be very low in the blood of healthy donors or melanoma 
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patients prior to specific immunotherapy [Chaux et al., 1998; Godelaine et al., 2003]. 
This low frequency could explain the absence of CTL response, as numbers of 
lymphocytes infiltrating the tumor specimens were relatively small and therefore the 
potential TCR diversity reduced. Most interestingly, expression of a number of CTA 
has recently been shown to take place also in the thymus [Gotter et al., 2004], 
thereby facilitating the induction of specific tolerance. 
 
Apparently, many tumors are able to avoid attacks of the immune system by tumor 
escape mechanisms, such as downregulation of MHC or antigens, or creation of a 
tumor microenvironment unfavourable to immunocompetent cells. Secretion of 
factors (e.g. Indoleamine 2,3-dioxygenase (IDO), transforming growth factor-β, IL-10) 
and induction of regulatory T cells are known to suppress anti-tumor immune 
responses [Kim et al., 2006; Uyttenhove et al., 2003]. Recently, T regulatory CD4+ 
cells expressing FoxP3 were found to be accumulated in NSCLC, especially in early 
stages [Ishibashi et al., 2006]. Furthermore, other studies suggested infiltration of 
IDO expressing cells as prognostic marker of poor survival in NSCLC [Astigiano et 
al., 2005]. 
Intervention of some of these tumor escape mechanisms, as a possible explanation 
for the low number of positive results obtained, was investigated. Expression of 
genes encoding inhibitory factors IL-10, IDO or expressed by regulatory T cells, such 
as FoxP3, was evaluated in the different NSCLC specimens. No major correlation 
between absence of CTL response or expression of CTA and levels of these genes 
could be observed.  
 
Tumor infiltrating lymphocytes freshly derived from surgically excised tumor 
specimens have been suggested to be anergic, unable to proliferate and to produce 
factors, such as IFNγ, upon T cell receptor triggering [Zippelius et al., 2004]. 
However, it has been demonstrated that TIL derived CD8+ cells can be expanded 
after purification and restimulation [Ratto et al., 1996]. Furthermore, in melanoma 
studies using TIL, these cells were shown to be indeed at least as efficient as 
peripheral lymphocytes in the generation of effector cells [Spagnoli et al., 1995]. 
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Peripheral blood T cells (PBL) may display a comparatively enhanced reactivity, 
possibly targeting a wider range of epitopes.  By testing naive PBL from healthy 
donors, in absence of any CTA expression, CTL responses specific for MAGE-A10, 
multi-MAGE-A and NY-ESO-1 could indeed be induced. In this case, to compensate 
the likely absence of pre-sensitization, high numbers of CD8+ T cells were stimulated 
with CT antigens. These data indicate that CTA cellular immune responses can be 
generated from appropriate pools of healthy donors’ T cells.  
However, despite attempts to generate similar responses from PBL of NSCLC 
patients, we were unable to raise CTL specific for the two epitopes tested.        
Optimal CTL activation depends on efficient antigen presentation by MHC molecules 
loaded through the class I endogenous pathway of antigen processing [Maffei et al., 
1997; Townsend et al., 1986; van Endert, 1999]. In contrast to the CTL response 
evaluation in NSCLC specimens, in healthy donors DC were derived from GM-CSF 
stimulated monocytes by using IFNα instead of IL-4. As recently shown, these cells 
were more effective antigen presenting cells than IL-4-DC [Lapenta et al., 2006]. Still 
unclear is whether generation of CTA specific CTL from PBL decisively depends on 
the use of a different subtype of DC as APC. 
 
This study also demonstrated the potential of DC pulsed-peptides as immunogenic 
reagents for stimulation of PBL in vitro. HLA-A*0201 restricted CTA epitopes were 
able to efficiently induce CTL responses mostly for MAGE-A10, but also for        
multi-MAGE-A and NY-ESO-1. Soluble peptides were used at high concentration, 
clearly saturating the antigen uptake of APC. However, the similar use of peptide 
MAGE-A4 for PBL stimulation of healthy donors did not induce any response even 
after numerous stimulations. Among the many possible reasons leading to these 
differences one may mention a lower immunogenicity of the epitope, peptide 
instability or a lower frequency of MAGE-A4 CTL precursors.  
Notably, the clinical use of peptides alone is limited by their rapid proteolytic 
digestion, leading to low bio-availability and poor immunogenicity. In contrast, tumor 
specific cell mediated immune responses could be elicited by infection of APC with 
recombinant viruses encoding multiple TAA, mimicking the endogenous pathway of 
antigen presentation by MHC class I molecules.  
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Vaccinia virus vectors were shown to be highly immunogenic and induce humoral 
and cellular responses [Graham et al., 1991]. Among others, our group demonstrated 
safety and immunogenicity of recombinant vaccinia viruses (rVV) in a phase I/II 
clinical trial in metastatic melanoma patients [Zajac et al., 2003]. Genes encoding 
costimulatory molecules such as CD80 and CD86 were also shown to enhance 
immune responses [Marti et al., 1997; Oertli et al., 2002].  
Based on previous experience, we constructed viral vectors encoding the different 
CTA epitopes assessed for immune response induction in NSCLC. Immunogenicity 
of this vector was demonstrated on a few TIL populations isolated from NSCLC 
specimens. Of note, in the one case where high CTL response was detected, 
response was induced by using rVVcombi-MAGE, containing minigenes encoding     
HLA-A*0201 restricted MAGE-A4, MAGE-A10, multi-MAGE-A and NY-ESO-1 
epitopes together with human CD80. Direct comparison of the use of peptides with 
the viral vector suggests the usefulness of vaccinia virus encoding epitopes as a 
potent vector for therapeutic vaccination. 
 
Our extensive work on 33 NSCLC specimens and on the reactivity of TIL leads us to 
the conclusion that CTA may be relevant targets for an immunotherapy approach in 
this disease. Indeed, their expression is frequent and often concomitantly detectable 
in individual samples. Spontaneous immune response toward CTA was observed 
only in one patient and generation of CTA specific CTL remains rare. However, we 
demonstrated that it is nevertheless possible to generate multiples cellular immune 
responses also from peripheral blood lymphocytes from healthy donors. 
Active specific immunotherapy approaches in NSCLC are currently limited. Phase I 
or II clinical trials have been reported using MUC1, HER-2/neu or telomerase 
peptides as well as whole protein MAGE-3 or EGF based vaccines [Atanackovic et 
al., 2004; Brunsvig et al., 2006; Gonzalez et al., 2003; Palmer et al., 2001; Salazar et 
al., 2003]. Beneficial clinical and immune responses have been described. In a phase 
II clinical study with cancer/testis protein MAGE-3, patients developed strong antigen 
specific CD4+ helper T cells along with specific antibodies and CD8+ T cell 
responses [Atanackovic et al., 2004].  
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However, these active specific immunotherapy trials are limited by the use of a single 
antigen. The in vitro and in vivo efficacy of our approach, based on an immunogenic 
vaccinia vector encoding for multiple antigens, was previously demonstrated for 
melanoma antigens. In the present study we showed the immunogenicity of a vector 
encoding CTA epitopes. Hence, it is tempting to speculate that a multi-CTA 
recombinant virus similar to the one described in this work might prove useful in the 
implementation of clinically effective antigen specific immunotherapy in NSCLC. 
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Annex I – CT Gene Database 
 
 
 
 
Gene Family CT Identifier Family Member CT Identifier 
MAGEA  
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 MAGEA1 
 MAGEA2 
 MAGEA3 
 MAGEA4 
 MAGEA5 
 MAGEA6 
 MAGEA8 
 MAGEA9 
 MAGEA10 
 MAGEA11 
 MAGEA12 
 
 CT1.1  
 CT1.2  
 CT1.3  
 CT1.4  
 CT1.5  
 CT1.6  
 CT1.8  
 CT1.9  
 CT1.10  
 CT1.11  
 CT1.12  
 
BAGE  
 
CT2 
 
 BAGE 
 BAGE2 
 BAGE3 
 BAGE4 
 BAGE5 
 
 CT2.1  
 CT2.2  
 CT2.3  
 CT2.4  
 CT2.5  
 
MAGEB  
 
CT3 
 
 MAGEB1 
 MAGEB2 
 MAGEB5 
 MAGEB6 
 
 CT3.1  
 CT3.2  
 CT3.3  
 CT3.4  
 
GAGE1  
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 GAGE1 
 GAGE2 
 GAGE3 
 GAGE4 
 GAGE5 
 GAGE6 
 GAGE7 
 GAGE8 
 
 CT4.1  
 CT4.2  
 CT4.3  
 CT4.4  
 CT4.5  
 CT4.6  
 CT4.7  
 CT4.8  
 
SSX  
 
CT5 
 
 SSX1 
 SSX2a 
 SSX2b 
 SSX3 
 SSX4 
 
 CT5.1  
 CT5.2a  
 CT5.2b  
 CT5.3  
 CT5.4  
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NY-ESO-1  
 
CT6 
 
 NY-ESO-1 
 LAGE-1a 
 LAGE-1b 
 
 CT6.1  
 CT6.2a  
 CT6.2b  
 
MAGEC1  
 
CT7 
 
 MAGEC1 
 MAGEC3 
 
 CT7.1  
 CT7.2  
 
SYCP1  
 
CT8 
 
 SYCP1 
 
 CT8  
 
BRDT  
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 BRDT 
 
 CT9  
 
MAGEC2  
 
CT10 
 
 MAGEC2 
 
 CT10  
 
SPANX  
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 SPANXA1 
 SPANXB1 
 SPANXC 
 SPANXD 
 
 CT11.1  
 CT11.2  
 CT11.3  
 CT11.4  
 
XAGE  
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 XAGE-1a 
 XAGE-1b 
 XAGE-1c 
 XAGE-1d 
 XAGE-2 
 XAGE-3a 
 XAGE-3b 
 XAGE-4 
 
 CT12.1a  
 CT12.1b  
 CT12.1c  
 CT12.1d  
 CT12.2  
 CT12.3a  
 CT12.3b  
 CT12.4  
 
HAGE  
 
CT13 
 
 HAGE 
 
 CT13  
 
SAGE  
 
CT14 
 
 SAGE 
 
 CT14  
 
ADAM2  
 
CT15 
 
 ADAM2 
 
 CT15  
 
PAGE-5  
 
CT16 
 
 PAGE-5 
 CT16.2 
 
 CT16.1  
 CT16.2  
 
LIPI  
 
CT17 
 
 LIPI 
 
 CT17  
 
NA88A pseudogene  
 
CT18 
 
 
NA88A 
pseudogene 
 
 CT18  
 
CTAGE-1  
 
CT21 
 
 CTAGE-1 
 CTAGE-2 
 
 CT21.1  
 CT21.2  
 
CSAGE  
 
CT24 
 
 CSAGE 
 TRAG3 
 
 CT24.1  
 CT24.2  
 
MMA1  
 
CT25 
 
 MMA1a 
 MMA1b 
 
 CT25.1a  
 CT25.1b  
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CAGE  
 
CT26 
 
 CAGE 
 
 CT26  
 
BORIS  
 
CT27 
 
 BORIS 
 
 CT27  
 
HOM-TES-85  
 
CT28 
 
 HOM-TES-85 
 
 CT28  
 
AF15q14  
 
CT29 
 
 AF15q14 
 
 CT29  
 
HCA661  
 
CT30 
 
 HCA661 
 
 CT30  
 
LDHC  
 
CT32 
 
 LDHC 
 
 CT32  
 
MORC  
 
CT33 
 
 MORC 
 
 CT33  
 
SGY-1  
 
CT34 
 
 SGY-1 
 
 CT34  
 
SPO11  
 
CT35 
 
 SPO11 
 
 CT35  
 
TPX1  
 
CT36 
 
 TPX1 
 
 CT36  
 
NY-SAR-35  
 
CT37 
 
 NY-SAR-35 
 
 CT37  
 
FTHL17  
 
CT38 
 
 FTHL17 
 
 CT38  
 
NXF2  
 
CT39 
 
 NXF2 
 
 CT39  
 
TDRD1  
 
CT41 
 
 TDRD1 
 NY-CO-45 
 
 CT41.1  
 CT41.2  
 
TEX15  
 
CT42 
 
 TEX15 
 
 CT42  
 
FATE  
 
CT43 
 
 FATE 
 
 CT43  
 
TPTE  
 
CT44 
 
 TPTE 
 
 CT44  
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Annex II – Publication  
 
 
 
 
Cancer/testis antigen expression and specific cytotoxic T lymphocyte 
responses in non small cell lung cancer. 
published in International Journal of Cancer (2007) 
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03/01 – 04/01 Research unit of Pathology, Centre Médical Universitaire, 
Genève, Switzerland: Study of JAM-2 molecule distribution in 
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17th meeting of the Swiss Immunology Ph.D Students, Wolfsberg, Switzerland - oral 
presentation 
 
 
2004   
  
European Cancer Center, 11th annual meeting, Mulhouse, France - poster presentation 
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